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OBJECTIVE OF THE STUDY
To examine metabolic abnormalities that characterizes pre-diabetes 
types for identifying more pre-diabetic subjects before they fall into the 
criteria  of  WHO  &  ADA and  providing  insight  into  development  of 
therapeutic strategies to slow/halt their progression into type 2 diabetes.
• To model and extract metabolic information harbored by the shape 
of the blood glucose curve during an OGTT (along with the level 
of glycemia).
• To identify a reliable yet simple indirect method for quantitative 
assessment of insulin release and insulin sensitivity. 
• To put forward cutoff values for different time points of OGTT & 
AUCg, to help diagnose IGR and diabetes. 
• To examine whether a composite measure (oral disposition index) 
is associated with the development of diabetes.
• To examine the hyperbolic relationship between the early insulin 
release and surrogate measures of insulin sensitivity for identifying 
different glucose tolerance categories. 
PURPOSE OF STUDY
India  has  the highest  prevalence  of  diabetes  accounting for 
nearly  one-sixth  of  the  world's  diabetic  patients.  The risk  factors 
peculiar for developing diabetes among Indians include high familial 
aggregation, central obesity, insulin resistance and life style changes 
due to urbanization. Most long standing macro and micro vascular 
complications  are  also  more  common  among  Indian  diabetics  as 
compared to other races and ethnic groups. The rising incidence of 
diabetes and its complications are going to pose a grave health care 
burden on our country.
 
Type 2 diabetes frequently goes undiagnosed for many years, 
because  hyperglycemia  develops  gradually.  Early  detection, 
diagnosis,  and early  treatment  of  diabetes  are  very  important  for 
preventing diabetic complications. Clinical trials have demonstrated 
that lifestyle intervention and pharmacological therapy in high-risk 
individuals reduce the incidence of type 2 diabetes. Thus, reliable 
models for identification of individuals at high risk for future type 2 
diabetes are essential  and have important  clinical  implications  for 
intervention programs.
The  quantitative  assessment  of  insulin  resistance  or  insulin 
sensitivity is of great importance in the study of epidemiology and 
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pathophysiology of major public health problems and in following 
the clinical course of patients on various therapeutic regimens.
Ability to easily assess insulin sensitivity would be useful for 
investigating the role of insulin resistance in the pathophysiology of 
type  2  diabetes  mellitus,  polycystic  ovary  disease  and  many 
metabolic  disturbances  associated  with  coronary  artery  disease, 
including obesity, dyslipidemia, and hypertension. Therefore, there 
is  a  need  for  an  accurate,  reproducible  and  simple  method  for 
measuring insulin resistance. 
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INTRODUCTION
The term diabetes mellitus describes a metabolic disorder of 
multiple  aetiology  characterized  by  chronic  hyperglycemia  with 
disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both. The effects 
of  diabetes  mellitus  include  long–term  damage,  dysfunction  and 
failure  of  various  organs.  Diabetes  mellitus  may  present  with 
characteristic symptoms such as thirst, polyuria, blurring of vision, 
and weight loss.  In its most  severe forms,  ketoacidosis or a non–
ketotic hyperosmolar  state  may develop and lead to stupor,  coma 
and, in absence of effective treatment, death.
A variety of causes can manifest as diabetes mellitus. While 
most  patients have Type 1 or Type 2 diabetes,  other types occur. 
Identifying the  cause  is  important  for  management  and prognosis 
(Alberti KGMM ,et al. 1998).
Table 1: Classification of diabetes mellitus
Type of
 Diabetes Features
Type 1 Absolute insulin deficiency following destruction of the beta-cells
Type 2
Relative insulin deficiency due to a 
combination of insulin resistance and 
impaired insulin secretion
Gestational Diabetes triggered by pregnancy and often remitting afterwards
Other Genetic or acquired
Other causes of diabetes or impaired glucose handling due to 
genetic cause primarily affecting insulin production or action:
(1) Genetic defect in beta-cell function
a. NeuroD1 and chromosome 2 (MODY 6)
b. Glucokinase and chromosome 7p (MODY 2)
c. HNF-1alpha and chromosome 12 (MODY 3)
d. Insulin promotor factor 1 and chromosome 13 (MODY 4)
e. HNF-1beta and chromosome 17 (MODY 5)
f. HNF-4alpha and chromosome 20q (MODY 1)
g. Mitochondrial DNA
(2) Genetic defect in insulin action (defect in insulin receptor, etc)
a. Type A insulin resistance
b. Leprechaunism
c. Lipoatrophic diabetes
d. Rabson-Mendenhall syndrome)
 
Other causes of diabetes or impaired glucose handling due to 
acquired causes:
(1) Disease of the exocrine pancreas
a. Pancreatitis
b. Cystic fibrosis
c. Hemochromatosis
d. Fibrocalculous pancreatopathy
e. Pancreatic tumor
f. Trauma or surgery
(2) Drug or chemical-induced
a. Corticosteroids
b. Treatment of aids
c. Organ transplantation (tacrolimus, other)
d. Thiazides
e. Interferon
f. Vacor
g. Nicotinic acid
h. Pentamidine
i. Second-generation anti-psychotic agents
j. Diazoxide
k. Dilantin
l. Beta-adrenergic agonists
m. Others
(3) Endocrinopathies
a. Acromegaly
b. Glucagonoma or somatostatinoma
c. Hyperthyroidism
d. Aldosternoma or Cushing's disease
e. Pheochromocytoma
(4) Viral infection-related
a. Cytomegalovirus (CMV)
b. Congenital rubella
(5) Immunologic disorders
a. Antibodies to insulin receptor
b. Stiff man syndrome
(6) Hereditary disorder associated diabetes (may include one or more 
of the above mechanisms)
a. Klinefelter's syndrome
b. Turner's syndrome
c. Friedrich's ataxia
d. Wolfram's syndrome
e. Prader-Willi syndrome
f. Down's syndrome
g. Myotonic dystrophy
h. Lawrence-Moon-Bardet-Biedl syndrome
i. Congenital porphyria
j. Others
Insulin  –glucose  dynamics: Glucose  tolerance  is  an 
expression  of  the  efficiency  with  which  homeostatic  mechanism 
restore  glycemia  to  basal  levels  after  perturbation.  Clinically,  the 
most assessment is following an oral glucose load ,a surrogate for a 
more  physiological  meal.  The  homeostatic  response  includes  an 
increase in insulin levels and, therefore, also the insulin dependent 
processes  that  lower  glycemia.  Theoretically  the  oral  glucose 
tolerance  test  should  yield  an  estimate  of  insulin  sensitivity,  if 
insulin  concentrations  are  measured.  Glucose  concentrations  also 
change in manner that is partly dependent on insulin, but also on 
gastric emptying and absorption. In general, therefore attempts have 
been made to isolate the glucose –insulin relationship, as much as 
possible, from other factors (Katz A, et al. 2000).
Insulin  is  an  essential  peptide  hormone  whose  metabolic 
actions  maintain  whole  body  glucose  homeostasis  and  promote 
efficient glucose utilization (Accili D, et al. 2003). Insulin stimulates 
increased  glucose  disposal  in  skeletal  muscle  and  adipose  tissue, 
whereas it inhibits gluconeogenesis in liver to help regulate glucose 
homeostasis. In addition to these classical insulin target tissues, there 
are many other important physiological targets of insulin, including 
the brain, pancreatic  ß-cells,  heart, and vascular endothelium, that 
help  to  coordinate  and  couple  metabolic  and  cardiovascular 
homeostasis under healthy conditions (Prodi E, et al. 2006). Insulin 
has  concentration-dependent  saturable  actions  to  increase  whole 
bodyglucose disposal. The maximal effect of insulin defines “insulin 
responsiveness,”  whereas  the  insulin  concentration  required  for  a 
half-maximal response defines “insulin sensitivity”.
Insulin sensitivity and insulin secretion are mutually  related 
such  that  insulin  resistance  is  compensated  by  increased  insulin 
secretion. A correct judgement of insulin secretion therefore requires 
validation in relation to the insulin sensitivity in the same subject.
INSULIN RESISTANCE
Insulin resistance/sensitivity is typically defined as decreased 
sensitivity or responsiveness to metabolic actions of insulin, such as 
insulin mediated glucose disposal and inhibition  of hepatic  glucose 
production(HGP). The concept of insulin resistance was proposed as 
early  as  (Himsworth  H,et  al. 1936)  to  describe  diabetic  patients 
requiring  high doses   of  insulin.  insulin  resistance  plays  a  major 
pathophysiological role in type2 diabetes and is tightly associated 
major  public  problems,  including  obesity,  hypertension, 
coronaryartery  disease  ,dyslipedemias  ,andcardiovascular 
abnormalities that define the metabolic syndrome.(Reaven GM,  et  
al. 2005,Petersen KF,  et al. 2007).A global epidemic of obesity is 
driving the increased incidence and prevalence of  type 2 diabetes 
and its cardiovascular complication(Giles TD,  et al. 2007).
Insulin sensitivity vs insulin secretion
Insulin  sensitivity  vs  insulin  secretion  –  the  hyperbolic 
relationship
It  had already been shown several  decades  ago that  insulin 
resistance such as in obesity is associated with an increased insulin 
secretion . Nevertheless, the close and inverse relationship between 
insulin  secretion  and  insulin  sensitivity  has  been  widely 
acknowledged only during recent years. An early attempt at finding 
a mathematical relationship between insulin sensitivity and insulin 
secretion as defined by the pancreatic sensitivity to glucose.
Fig1: Insulin sensitivity and insulin secretion 
an hyperbolic relationship
In recent years different mathematical formulas for measuring 
insulin resistance have been developed .(Hosker JP et al. 1985).these 
mathematical  formulas use serum glucose and insulin levels(Quon 
MJ  et  al. 2001)  either  when  patients  are  fasting  or  during  oral 
glucose  tolerance  test(OGTT),which  is  considered  to  be  a  good 
physiological initiator of meal stimulation (Cederholm J et al. 1990).
SIMPLE  SURROGATE  INDEXES  FOR  INSULIN 
SENSITIVITY/RESISTANCE
In  healthy  humans,  the  fasting  condition  represents  a  basal 
steady  state  where  glucose  is  homeostatically  maintained  in  the 
normal range such that insulin levels are not significantly changing 
and HGP is constant;  i.e,  basal  insulin secretion by pancreatic –β 
cells determines a relatively constant level of insulinemia that will 
be lower or higher in accordance with insulin sensitivity/resistance 
such that HGP matches whole body glucose disposal under fasting 
conditions.
A  critical  condition  and  assumption  of  simple  surrogate 
indexes is that subjects are strictly fasting and in a basal steady-state 
condition with respect to glycemia, insulinemia, and HGP. Surrogate 
indexes based on fasting glucose and insulin concentrations reflect 
primarily hepatic insulin sensitivity/resistance. However, undermost 
conditions, hepatic and skeletal muscle insulin sensitivity/resistance 
are  proportional  to  each other. Therefore,  definitions of  the more 
useful surrogate indexes take these considerations into account. Due 
to  lack  of  a  standardized  insulin  assay,  it  is  not  possible  to  use 
surrogate  indexes  to  define  universal  cutoff  points  for  insulin 
resistance.
General advantages and appropriate usage:
 Simple surrogate indexes of insulin sensitivity/resistance are 
inexpensive quantitative tools that can be easily applied in almost 
every setting, including epidemiological studies, large clinical trials, 
clinical research investigations, and clinical practice.
Table 2: Insulin Sensitivity Indices
Index Equation
INS-1 1/INS0
GLUCOSE TO 
INSULIN RATIO  GLU0/INS0
HOMA IR I0G0/22.5
RAYNAUD 40/INS0
BELFOIRE(F
) 
2 I0G0+1
FIRI-1 1/ I0* G0/22.5
QUICKI 1/LOG I0 /LOG G0
INS120-1 1/1NS120
GLUCOSE INSULIN 
AUC   AUCGLU/AUCINS
MCAULEY Mffm/I=e(2.63-0.2*ln(I0)-0.31 ln (TAG0)
CEDERHOL
M 75000+(G-2HG)*(1.15*180)*0.19*m)120* Gmean *log (I mean)
BELFOIRE(OG)  2/IAUC*GAUC+1
DRIVSHOLM GLU AUC/INS AUC
GUTT
[75.000+(fasglu-
2hglu)*0.19*bw]/120min
ISI MAT
SUDA     
10000
√GLU*INS*GLUMEAN*INSMEAN
SOONTHURNPUN
[1.9/6*BW*G+5201.9/18*BW*GAUC*GU/1.
8]*1000
(IAUC*BW)
AVIG NON
SiB
Si2h
VD
[(0.317*SiB)+Si2h]/2
108/I0*G0*VD
108/I120*G120*VD
150*BW
INSULIN SENSITIVITY INDICES
INS-1 -1/INS0  (1/  FASTING  INSULIN):  In  healthy  subjects, 
elevations  in  fasting  insulin  levels  (with  normal  fasting  glucose 
levels)  correspond  to  increased  insulin  resistance.  Indeed,  in 
nondiabetic  subjects,1/(fasting  insulin)  is  a  well-known proxy  for 
insulin  sensitivity  that  decreases  as  subjects  become more  insulin 
resistant  (and  fasting  insulin  levels  rise)  .(Laako  et  al. 1993). 
However, insulin concentrations are not normally distributed. Thus, 
linear  correlations  between  1/(fasting  insulin)  and  estimates  of 
insulin  sensitivity  from the glucose  clamp are  not  that  strong.  In 
addition, this index does not take into account the inappropriately 
low insulin secretion in the face of hyperglycemia seen in diabetic 
subjects  or  glucose-intolerant  subjects.  Consequently,  using  1/
(fasting insulin) as a measurement of insulin sensitivity/resistance in 
patients  with  glucose  intolerance  or  type  2  diabetes  who  have 
diminished pancreatic reserve leads to erroneous results.
GLUCOSE TO INSULIN RATIO  -GLU0/INS0 (Glucose/insulin 
ratio): A number of studies (Silfen ME, et al. 2001,Vuguin P, et al. 
2001) have used the fasting glucose/insulin ratio (G/I ratio) as an 
index of insulin resistance In the case of nondiabetic subjects, the 
G/I ratio is essentially functionally equivalent to 1/(fasting insulin) 
since fasting glucose levels are all in the normal range. However, the 
G/I ratio does not appropriately reflect the physiology underlying the 
determinants  of  insulin  sensitivity  (Quon  MJ  ,  et  al. 2001).  For 
example, given the same level of relative fasting hyperinsulinemia in 
a  diabetic  and  a  nondiabetic  insulin-resistant  subject,  1/(fasting 
insulin) remains unchanged. However, under these same conditions, 
the G/I ratio paradoxically and erroneously increases in the diabetic 
subject.  Therefore,  the  fasting  G/I  ratio  is  a  conceptually  flawed 
index of insulin sensitivity.
HOMA-( Homeostasis  model  assessment): Homeostasis  model 
assessment (HOMA), developed in 1985 (Mathews DR,  et al. 2001) 
is a model of interactions between glucose and insulin dynamics that 
is  then  used  to  predict  fasting  steady-state  glucose  and  insulin 
concentrations for a wide range of possible combinations of insulin 
resistance and  ß-cell  function. Both the original HOMA and then 
updated HOMA2 assume a feedback loop between the liver and    ß-
cell  (Wallace  TM  et  al. 2004)  i.e.,  glucose  concentrations  are 
regulated by insulin-dependent HGP, whereas insulin levels depend 
on the pancreatic  ß-cell  response to glucose concentrations. Thus, 
deficient ß-cell function reflects a diminished response of  ß-cell to 
glucose stimulated insulin secretion . Likewise, insulin resistance is 
reflected  by  diminished  suppressive  effect  of  insulin  on  HGP. 
HOMA  describes  this  glucose  insulin  homeostasis  by  a  set  of 
empirically derived nonlinear equations.
HOMA IR- IG/22.5
HOMA-IR  -   {[fasting  insulin  (µU/ml)]*  [fasting  glucose 
(mmol/l)]}/22.5.  The denominator of 22.5 is a normalizing factor; 
i.e,  the  product  of  normal  fasting  plasma  insulin  of  5  U/ml  and 
normal fasting plasma glucose of 4.5mmol/l typical of a “normal” 
healthy individual = 22.5. Therefore, for an individual with “normal” 
insulin sensitivity,HOMA-IR = 1. HOMA-IR has a reasonable linear 
correlation  with  glucose  clamp  and  minimal  model  estimates  of 
insulin sensitivity/resistance in several studies of distinct populations 
(Radziuk  J , et al. 2000). The coefficient of variation for HOMA-IR 
varies considerably depending upon the number of fasting samples 
obtained and the type of insulin assay used (Bonora E , et al. 2000). 
Quantitative  insulin  sensitivity  check  index.  Quantitative  insulin 
sensitivity  check  index  (QUICKI)  is  an  empirically  derived 
mathematical  transformation  of  fasting  blood glucose  and plasma 
insulin  concentrations  that  provides  a  reliable,  reproducible,  and 
accurate  index  of  insulin  sensitivity  with  excellent  positive 
predictive power (Chen H et al. 2005).
Quantitative  insulin  sensitivity  check  index  (QUICKI).  Like 
HOMA,  QUICKI  can  be  applied  to  normoglycemic  and 
hyperglycemic patients. It is derived by calculating the inverse of the 
sum  of  logarithmically  expressed  values  of  fasting  glucose  and 
insulin: 
            1  
[log(I0) + log(G0)]
Many investigators believe that QUICKI is superior to HOMA 
as a way of determining insulin sensitivity, although the two values 
correlate well. As the SI decreases, QUICKI values increase.
OGTT or  a  meal  to  determine  insulin  sensitivity/resistance 
(Cobelli C et al. 2007). Glucose disposal after an oral glucose load 
or a meal is mediated by a complex dynamic process that includes 
absorption, glucose effectiveness,  neuro hormonal actions, incretin 
actions,  insulin  secretion,  and  metabolic  actions  of  insulin  that 
primarily  determine  the  balance  between  peripheral  glucose 
utilization  and  HGP.  Surrogate  indexes  that  depend  on  dynamic 
testing  take  into  account  both  fasting  steady-state  and  dynamic 
postglucose load plasma glucose and insulin levels.
MCAULEY  INDEX:  The  authors(MCAULEY  et  al. ,  2001) 
proposed  a  formula  for   predicting  insulin  resistance  in 
normoglycemic individuals. regression analysis was used to estimate 
the cut –off  points and the importance of various data for insulin 
resistance(fasting  concentration  of  insulin  ,triglycerides,  aspartate 
amino transferase ,BMI, waist circumference).A bootstrap procedure 
was used to find an index , corrected for fat –free mass obtained by 
hyperinsulinemic  euglycemic  clamp(Mffm/I).An insulin  sensitivity 
obtained from HEC of  <  6.3 (expressed as glucose disposal rate in 
milligrams  per  kilogram  per  minute  divided  by  average  plasma 
insulin  concentration  in  (mIU/l)  and  triglycerides(TAG,mmol/l) 
showed the best prediction of insulin resistance as follows:
MCAULEY –Mffm/I=e(2.63-0.2*ln(I0)-0.31 ln (TAG0)
BELFOIRE INDEX: The condition for calculation of the belfoire 
formula is the definition of the normal value for basal glucose and 
insulin concentrations for mean normal value for glucose and insulin 
areas  during  OGTT(Belfoire  et  al. ,  1998).the  main  point  of  the 
belfoire  formula  is  the  comparison  of  insulin  and  glucose  values 
measured .
BELFOIRE(OG)  -  2/IAUC*GAUC+1
IAUC- Insulin area under the curve
GAUC-Glucose area under the curve.
(or) it can be written as  ISI Belfoire – 2/Gs/GN *IS/IN +1
Gs,GN   - plasma glucose concentrations expressed as fasting values 
or as obtained during a standard OGTT at 0 and 2h areas are equal to 
GS,N = G0 + G120) or at 0,1 and 2 h (0-1-2h areas are equal to GS,N 
= ½ (G0 +G60+G120 );
IS,IN – Plasma insulin concentrations expressed as fasting values or 
areas obtained during a standard OGTT at 0 and 2h (0-1-2h areas are 
equal to IS,N= I0+I60+I120 ).
The  subscript  S  and  N  refer  to  “subjects”  and  “normal 
reference values”,  respectively.  insulin sensitivity  calculated using 
these formulas can achieve only values between 0 and 2.In subjects 
with  normal  insulin  sensitivity  is  it  around  1;  in  overweight 
subjects  ,in  subjects  with  impaired  glucose  tolerance  and  with 
diabetes type 2 this value is below 1.correlation coefficient between 
between ISIBelfoire and HEC were in the original sudy reported to be 
0.93-0.99 other authors found lower correlation coefficients of these 
formulas  with  HEC  :0.65  ;  in  subjects  with  normal  glucose 
tolerance,0.54;  in  subjects  with  impaired  glucose  tolerance,  and 
0.48 ; in subjects with diabetes type 2.
Matsuda:  The  index of whole  body insulin sensitivity –proposed 
by Matsuda and  Defronzo et al. (1999) combines both hepatic and 
peripheral insulin sensitivity. this index is calculated from plasma 
glucose (mg/dl) and insulin(mIU/ml). concentrations in fasting state 
and during OGTT. the correlation coefficients between ISI matsuda 
and HEC  were 0.73 in subjects with normal glucose tolerance ,0.66 
in subjects with  impaired glucose tolerance and 0.60 in nondiabetic 
subjects.  however  in  subjects  with  diabetes  mellitus  type  2  the 
correlation proved to be weaker 0.54.   
MATSUDA         -          10000/√G*I*GAUC*IAUC
I0 - fasting pasma insulin concentration
G0 - fasting glucose concentration
Gmean - mean plasma glucose concentration during 
OGTT
  I mean - mean plasma insulin concentration during 
OGTT
10000 - Simplifying constant to get  numbers from 
0 to 12
√ - correction of the nonlinear values 
distribution.
GUTTINDEX:  [75.000+(fasglu-2hglu)*0.19*bw]/120min
The  index  correlates  well  with  direct  estimates  of  insulin 
sensitivity obtained from the glucose clamp study  (GUTT M et al. 
2000).In  a  large  prospective  study,  this  index  was  the  best  at 
predicting  onset  of  type  2  diabetes  when  compared  with  other 
surrogate indexes derived from dynamic tests (including Avignon, 
Belfiore, and Stumvoll)
Where the term- (0.19 *BW) denotes glucose space, and BW 
is body weight (kg).
Mean of the 0- and 120-min glucose values from the OGTT). The 
mean  serum  insulin  (MSI,  mU/l)  is  the  mean  plasma  insulin 
concentrations  obtained  from the  0-  and  120-min  samples  of  the 
OGTT.
CEDERHOLM INDEX: The insulin sensitivity index proposed by 
cederholm  and  wibell  et  al.,  1990)  represents  peripheral  insulin 
sensitivity  and  muscular  uptake,  due  to  the  dominant  role  of 
peripheral tissues in glucose disposal after an oral glucose load.
CEDERHOLM - 75000+(G2HG)*(1.15*180)*0.19*m) 
             120* Gmean *log (I mean)
where 
75000 - oral glucose load in an OGTT in mg.
G0 - fasting  plasma  glucose  concentration 
(mmol/l),
G120  -  plasma glucose concentration in the 120th min of 
OGTT(mmol/l),
1.15  -  factor  transforming  whole  venous  blood 
glucose 
to  plasma  values  (not  necessary  ,if  glucose 
concentration is estimated in plasma),
180  - Conversion  factor  to  transform  plasma 
glucose 
concentration from mmol/l in to mg/l,
0.19 - glucose space in liter per kg of weight,
m - Body weight(kg),
120 - Duration of OGTT(min)
Imean - Mean plasma insulin concentration during 
OGTT(mU/l)
Gmean  - mean plasma glucose concentration during 
OGTT(mmol/l).
values found in normal non-obese individuals were reported to 
be  about  79  + 14  mg.l2 .mmol-1.mU-1.min-1 ,lower  in  obese 
individuals  ,  in  subjects  with  impaired  glucose  tolerance  and  in 
patients with type2 diabetes. Determined correlation coefficients of 
this index with HEC: 0.52 in subjects with normal glucose tolerance, 
0.48 in subjects with impaired glucose tolerance and 0.40 in subjects 
with diabetes type2.
Other  authors  (stumvoll  et  al.,  2000)  determined 
correlation coefficients of this index with HEC and found to 
be 0.60 in non –diabetic subjects.
AVIGNON  INDEX:  The  authors  (Avignon  et  al. ,  1999) 
proposed  3  insulin  sensitivity  indices:  Sib  (derived  from 
fasting  plasma   insulin  and  glucose  concentrations)  ,  Si2h 
(derived from plasma insulin  and glucose  concentrations  in 
the 120th min of OGTT) and Sim (derived by averaging Sib 
and Si2h after balancing by a coefficient of 0.137 to give the 
same weight to both indices).
AVIGNON-[(0.317*SiB)+Si2h]/2
1. SiB 108/I0*G0*VD
2. Si2h 108/I120*G120*VD
3. VD 150*BW
I  and  G  represent  the  plasma  concentrations  of 
insulin(mIU/l)and glucose (mmol/l) respectively. VD is the glucose 
distribution volume calculated using a monocompartmental model: 
VD=150ml/kg of body weight.   
The  SiM  index correlated well with insulin sensitivity 
obtained  during  insulin  –  modified  frequently  sampled 
intravenous glucose  tolerance  test  (FSIVGTT)  (Bergman  et  
al. ,  1987)  in  individuals  with  normal  glucose  tolerance 
(0.89)  ,  with  impaired   glucose  tolerance  (0.96),  and  in 
patients with diabetes mellitus type 2 (0.83). it is important to 
note that other indices were correlated with the  clamp method 
, seen as the “gold standard” in estimating insulin sensitivity. 
The correlation coefficients of FSIVGTT and the euglycemic 
clamp were reported to be 0.84(Beard et al., 1986), 0.89
and  0.62  (Saad   et  al. ,  1994),diminishing  the  weight  of 
Avignon indices to the level of other indices discussed above.
INSULIN SECRETION / RELEASE:
BETA CELL FUNCTION: It is well established that 
abnormalities in insulin secretion are an important determinant 
of  diabetes mellitus  and other states  of  glucose intolerance. 
However,  assessment  of  β-cell  function  in  humans  under 
physiological conditions has been a challenge because of its 
complex interplay with other key system variables. Although 
β-cell  function  commonly  is  inferred  from  plasma  insulin 
concentrations,  this  approach  introduces  error  due  to  the 
confounding effect of hepatic insulin extraction. On the other 
hand,  concordant  measurement  of  C-peptide  and  insulin 
concentrations  enables  simultaneous  assessment  of  insulin 
secretion  and  hepatic  insulin  extraction.  An  additional 
difficulty  is  that  measurement  of  insulin  secretion  alone 
provides  limited  insight  because  appropriateness  of  β-cell 
function must be interpreted relative to the prevailing level of 
insulin  action.  Since the primary goal  of  most  studies is to 
determine  how alterations  in   β-cell  function  as  well  as  in 
insulin  action  and  hepatic  insulin  extraction  influence 
carbohydrate,  fat,  and  protein  metabolism,  ideally  these 
should be assessed under physiological conditions by using a 
single,  simple  physiological  test,  i.e.,  in  the  presence  of 
glucose, amino acids, incretins, and neural signals. Models of 
insulin  secretion  enable  evaluation  of  beta  cell  function 
following  intravenous  injection  of  bolus  of  glucose  during 
IVGTT or after ingestion of glucose during OGTT or a mixed 
meal.  The  oral  perturbation  are  more  physiological  than 
intravenous once  with incretin  effect  in  operation and with 
meal  being  superior  to  OGTT  because  of  presence  of 
nutrients.  Insulin  action  and  hepatic  extraction  also  can  be 
assessed by models during IVGTT and OGTT meal.
Fig:2  Representative  β -cells  discharging insulin  into an  islet  capillary loop. 
Major steps preceding insulin secretion are synthesis  (not shown),  proinsulin 
processing to insulin and vesicle transport and docking to membrane,  vesicle 
priming,  and  then  insulin  discharge  from  vesicle  into  capillary  as  either  a 
fraction  of insulin  contents  (kiss and run illustrated  in  cell  A) or  all  insulin 
contents (exocytosis in cell B).
INSULIN SECRETION INDICES:
Table 3: Insulin Secretion Indices
Index Equation
HOMA B 20 I0/G0-3.5
STUMVOLL 0.22-0.0032*BMI-.0000645*2hi-0.0037*G90
½ II I½- I0/ G0½- G0
2h II ∆IAUC/∆GAUC
HOMA-S 3.33 I0/ G0-3.5
HOMA B - 20 I0 /G0-3.5  Computer  simulations  have been 
used  to  generate  a  normogram  from  which  mathematical 
transformations of fasting glucose and insulin data from individual 
subjects determine unique combinations of SI (HOMA%S) and  ß-
cell function (HOMA%B) from steady-state conditions. The updated 
HOMA2 accommodates assessment of HOMA%S and HOMA%B 
in subjects with glucose levels <25 mM, accounts for renal glucose 
losses, assumes reduced suppression of HGP and increased insulin 
secretion in response to glucose levels >10 mM, and allows for the 
use  of  total  or  specific  insulin  assays.  An  important  caveat  for 
HOMA%B  (determined  from  fasting  glucose  and  insulin 
concentrations) is that it imputes a dynamic  ß -cell function (i.e., 
glucose stimulated insulin secretion) from fasting steady-state data.
Where   I0  -  fasting insulin (µU/ml)
           G0  - fasting glucose (mmol)
HOMA2 model generates model-derived estimates of %B and 
%S, rather than linear approximations. It took account of 
1. Variations in hepatic & peripheral glucose resistance, 
2. Increases  in  the  insulin  secretion  curve  for  plasma  glucose 
concentrations above 10 mmol/L (180 mg/dL) and 
3. The contribution of circulating proinsulin . 
The model was recalibrated also to give %B and %S values of 
100% in normal young adults when using currently available assays 
for insulin, specific insulin or C-peptide.
STUMVOLL INDEX: (Stumvoll et al., 2001) proposed a series of 
indices (approximately 10) calculated from plasma glucose (mmol/l) 
and  insulin  (pmol/l)  concentrations  during  OGTT.  The  equations 
were  generated  using  the  multiple  linear  regression  analysis  and 
adapted to the availabilities of sampling time during OGTT and of 
demographic  parameters  (BMI).their  correlation  coefficients  with 
HEC were in range between 0.62 and 0.79.
STUMVOLL - 0.22-0.0032*BMI-0.0000645*2hI-0.0037*G90
β-CELL FUNCTION FROM BASAL MEASUREMENTS
The  easiest  and  thus  most  popular  assessment  of   β-cell 
function is  the homeostatic  responsively index HOMA-B, derived 
from basal measurements of insulin and glucose (Matthews DR  et  
al. 1985) HOMA-B is widely used because of its  simplicity, it  is 
worth  pointing  out  that  it  reflects  the  release  of  insulin  under 
nonstimulated  conditions.  The  homeostatic  model  HOMA-S  also 
provides  an  index  of  insulin  sensitivity  under  nonstimulated 
conditions, thus permitting evaluation of  ß-cell function in relation 
to the prevailing insulin action. It should be noted that an hyperbolic 
relationship between the two indexes is inherent in the calculation, 
since  HOMA-B  *  HOMA-S  is  a  function  of  basal  glucose 
concentration such that the two measurements are, by definition, in a 
given subject hyperbolically inversely related provided basal glucose 
[and also basal insulin if the computer model HOMA-S (Levy JC et  
al. 2004) is used] remains constant (Caumo A ,et al. 2006).
Beta cell function and insulin sensitivity can be assessed by 
both IVGTT and OGTT minimal model indexes:
Hepatic Insulin Extraction: (FROM IVGTT):
Since plasma insulin concentrations are measured during the 
IVGTT  for  estimating  insulin  sensitivity,  posthepatic  insulin 
delivery  rates  can  be  calculated  allowing  estimation  of  hepatic 
insulin  extraction  during  the  test,  HEivgtt,  and  in  basal  condition, 
Heb(Toffolo G et al. , 2006)  . To this end, the protocol of choice is 
an insulin-modified IVGTT, since the decay of insulin concentration 
observed after exogenous insulin administration facilitates a reliable 
estimation  of  insulin  kinetics.  However,  a  population  approach, 
similar to that developed for C-peptide kinetics, is being developed 
for  insulin  kinetics,  and preliminary  results  are  very  encouraging 
(Campioni M et al., 2004).
First- and Second-Phase Indexes and Delay Based on C-Peptide:
AIR has two major limitations. First, it is a composite “β -cell 
function and hepatic insulin extraction” index, and second, it probes 
ß -cell behavior in a very brief time window and immediately after a 
markedly supraphysiological glucose stimulus.  ß-Cell function can 
be  assessed  from  plasma  glucose  and  C-peptide  concentrations 
measured during a standard or insulin- modified IVGTT by using the 
minimal  model. Insulin secretion is  made up of  two components, 
first-  and  second-phase  secretion  .First  phase  introduces  a 
derivative  control,  since  it  is  proportional  to  the  rate  of 
increase of glucose from basal up to the maximum through the 
parameter  Ø 1, which defines the first responsively index (in 
contrast to AIR,Ø 1 is a pure ß-cell function index; correlation 
between  AIR  and  Ø 1 in  204  individuals  is  0.72). Second-
phase  insulin  secretion  is  believed  to  be  derived  from the 
provision and/or docking of new insulin secretory granules that 
occurs in  response to  (i.e.  proportional  to)  a given glucose 
concentration  through  the  parameter  Ø2,  which  defines  the 
second-phase responsively index, and reaches the releasable 
pool with a delaytime constant, T. 
IVGTT Minimal Model Indexes
BETA CELL RESPONSIVITY:
• Basal  Øb(min-1)  –  basal  secretion  per  unit  basal  glucose 
concentration 
• 1st phase Ø1 (10-9min-1)  –  amount  of  first  phase  secreted 
insulin per unit increase of glucose concentration.
• 2nd phase  Ø2 (10-9min-1)  -   over  basal  average  second 
phase  insulin  secretion  per  unit  over  basal  average  glucose 
concentration.
• Delay  T  (min)  –  delay  between  2nd phase  secretion  and 
glucose concentration.
• Total Øivgtt(10-9min-1) – over all responsivity from Ø1 and Ø2
• SI  ivgtt (10-5 min-1 per  pM)  –  effect  of  insulin  to  stimulate 
glucose disposal and inhibit glucose production.
DISPOSITION INDEX 
• 1st phase DI1 (10-14 dl.kg -1 min-1) – Ø1 * SIivgtt 
• 2nd phase DI2 (10-14 dl.kg -1 min-1) – Ø2 * SIivgtt
• Total DIivgtt (10-14 dl.kg -1 min-1per pM) – Øivgtt * SIivgtt 
HEPATIC INSULIN EXTRACTION
• Heb (%) – basal insulin extraction minus basal post hepatic 
delivery rate over basal insulin secretion.
• HE  ivgtt(%)  –  average  insulin  secretion  minus  average  post 
hepatic delivery over average insulin secretion during ivgtt.
There is also ogtt minimal model indices for calculating 
beta cell responsivity and insulin sensitivity sama as that of 
IVGTT minimal model indices. 
 Insulin secretion is the main defect seen in prediabtes stages 
and  in maturity onset of diabetes in young.
PREDIABETES: The prediabetes stages are of three types:
1. IFG – IMPAIRED FASTING GLUCOSE
2. IGT- IMPAIRED GLUCOSE TOLERANCE
3. combined IFG and IGT  
The term prediabetes refers to subjects with impaired 
glucose  and  /or  impaired  fasting  glucose  tolerance  or 
combined  IFG/IGT  who  are  at  increased  risk  for  type  2 
diabetes  mellitus.  Although  both  types  of  patients  are  at 
increased  risk  for  developing  type  2  diabetes  mellitus  and 
cardiovascular  disease,  they  manifest  distinct  metabolic 
abnormalities.  (Muhammad A. Abdul –ghani ,  et  al. 2009). 
During  past  decade  ,physiological  studies  have established 
that  IFG and  IGT are  caused  by  different  abnormalities  in 
insulin secretion and action.
EPIDEMIOLOGY OF PREDIABETES:
• Epidemiologic studies demonstrated that IFG (110-125mg/dl) 
has lower prevalence than IGT because most  of the studies 
were  done  prior  to  2003,  an  fpg  concentration  of 
110mg/dl(6.1Mm) was used as lower cut  off point defining 
IFG.
• A  minority  of  subjects  with  IGT  (20%-25%)  had 
concentration  an  fpg  concentration  of  more  than 
110mg/dl(6.1Mm)
• Over half subject with IFG had 2hr pg concentration of less 
than 140mg/dl (7.8Mm) (Muhammad A. Abdul –ghani et al 
2009).
• The absolute prevalence of IFG and IGT are ethnic dependent.
• For  example  the  prevalence  of  IGT varies  from as  low as 
6.3% in Chinese population (Chan JC et al., 1997) to as high 
as 20.3% in a Swedish population (Larson H et al., 1998)
• IGT is more frequent in women whereas the prevalence IFG is 
more than two fold  higher in men (Nakagami et al., 2003).
• IFG and IGT differ not only in their prevalence in the general 
population but also in their age and sex distribution.
Table 4: Pathophysiology of Prediabetes Stages
PATHOPHYSIOLOGY IFG IGT IFG/IGT
Muscle
a. Insulin sensitivity Unaltered Reduced Reduced
Liver
a. Insulin sensitivity
  
b. Hepatic glucose 
production
Reduced
Elevated
Unaltered
Unaltered
Reduced
Elevated
Pancreas
a.  First  phase  insulin 
response
b. Disposition index*
c. Glucagon secretion
Reduced
Reduced
Elevated
Reduced or 
unaltered
Reduced
Elevated
Reduced
Reduced
Elevated
Gut
a.Glp-1 secretion
b.Gip secretion
Reduced or 
elevated
Unaltered
Reduced or 
unaltered
Reduced or 
unaltered
Not studied
Not studied
Adipose tissue
a. Insulin sensitivity
b. NEFA release
Reduced
Unaltered
Reduced
Elevated
 
Not studied
Not studied 
Adipocytokine release
a. Brain
b. kidney
Not studied
Not studied
Not studied
Not studied
Not studied
Not studied
Table 5: Effects of aetiological factors on FPG levels (the 
development of IFG) ,2hPGlevels(the development of 
IGT),and combined FPG/2hPG levels (the development of 
IFG/IGT)
Ateiology FPG levels -IFG
2h PG levels-
IGT
FPG/2hPG-
IFG/IGT
Environmental factors
a. Physical activity
b. Low dietary quality
c. Smoking
No effect
No effect
Increase
Increase
Increase
No effect or 
increase
Not studied
No effect
Increase
Heritability
a.  Family history of 
diabetes
b. TCF7L2
C. MTNR1B
D. GCK
E. GCKR
F. G6PC2
G. FTO
H. PPARG
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Increase
No effect
Increase
No effect
Increase
No effect
No effect
No effect
No effect
Increase
Not studied
Not studied
Not studied
Not studied
Not studied
Not studied
Not studied
Sex and anthropometry
a. Male sex
b. Low birth weight
c. Short adult stature
Increase
Increase
No effect
No effect
Not studied
Not studied
Maturity onset diabetes of the young 
Maturity onset diabetes of the young (MODY (NIH) refers to 
any of several hereditary forms of diabetes caused by mutations in 
an autosomal  dominant gene (sex independent,  i.e.  inherited from 
any  of  the  parents)  disrupting  insulin  production.  Unlike  the 
polygenic recessive types 1 and 2 of diabetes caused by mutations in 
genes inherited from both parents, MODY is monogenic and easier 
to manage than polygenic ones.  As of  2004, six types have been 
enumerated, but more are likely to be added. MODY 2 and MODY 3 
are  the  most  common  forms.  The  severity  of  the  different  types 
varies  considerably,  but  most  commonly  MODY acts  like a  very 
mild  version  of  type  1  diabetes,  with  continued  partial  insulin 
production and normal insulin sensitivity. MODY may be confused 
with type 1 or type 2 diabetes. It is not young-onset type 2 diabetes 
(in a young person), as might erroneously be inferred from the name.
Table 6: Classification of different types of MODY
(Maturity onset of diabetes of the young)
Mody 
types
Chromo
- somes Gene
Omim
(gene)
Omim
(pheno) Frequency
Clinical
Features
Therapeutic
Intervention
Mody1 20 HNF4A 600281 125850 Rare
Macrosomia 
Transient 
hyperinsulinemic 
hypoglycemia,
Familial 
hyperlipidemia
Insulin, 
sulphonyl 
urea
Mody2 7 GCK 138079 125851 Frequent
Mild  insulin 
deficiency,  low 
Birth  weight 
infants,  neonatal 
diabetes  mellitus 
in homozygous
Diet, exercise
Mody3 12 HNF1A 142410 600496 Frequent
Pancreatic 
exocrine failure,
Increased 
sensitivity  to 
sulphonyl urea
Insulin
Mody4 13 IPF1 600733 606392 Rare
Pancreatic 
agenesis Insulin
Mody5 ---- HNF1ß 189907 137920 Frequent
Agenesis  of 
pancreatic  tail 
and  body, 
pancreatic 
exocrine failure
Insulin
Mody6 ----- NEUROD1 601724 606394 Rare Pancreatic anomalies
Insulin
Mody7 ---- KLF11 610508 ---- Rare Pancreatic malignancy
Insulin
Mody8 ---- CEL 609812 ---- Rare
Pancreatic 
exocrine  and 
endocrine failure
insulin
Mody9 ---- PAX4 612225 ---- Rare Diabetes mellitus -----
Permanent 
Neonatal
Diabetes 
mellitus
----- KCNJ11 606176 ----- ------ ------- ------
Transient
Neonatal 
diabetes 
mellitus
----- ABCC8
601410
610374
610582
---- -----
Some  forms  of 
neonatal  diabetes 
are permanent
----
METHODS  FOR  MEASURING  INSULIN 
SENSITIVITY:
Insulin  sensitivity  is  used  to  assess  hepatic  insulin 
sensitivity and peripheral insulin sensitivity. The concept of 
insulin  resistance  is  relatively  easy  to  understand,  but 
determining  precisely  who  is  insulin  resistant  is  more 
complicated. The relationship between glucose and insulin is 
quite complex and involves the interaction of many metabolic 
and regulatory factors.
Direct measures of insulin sensitivity
1. Hyperinsulinemic Euglycemic Clamp Technique 
2. Insulin Suppression Test
Hyperinsulinemic  euglucemic  clamp  technique  (GOLD 
STANDARD  TECHNIQUE):  this  glucose  clamp  technique 
originally developed by (DeFronzo et al. 1936) ,is a widely accepted 
as the reference  standard  for directly determining metabolic insulin 
sensitivity in human.
Procedure and concept:
After an overnight fast ,insulin is infused intravenously 
at a constant rate that may range from 5 to 120 mU.m-2.min-
1(dose per body surface area per minute).this constant  insulin 
infusion results in a new steady state insulin level that is above 
fasting  level  (hyperinsulinemic).As  a  consequence  ,glucose 
disposal  in skeletal  muscle  and adipose tissue   is  increased 
,whereas  HGP is  suppressed  .under  these  conditions  ,a  bed 
side  glucose  analyzer  is  used  to  frenquently  monitor  blood 
glucose level at 5 to 10-min intervals while 20% dextrose is 
given  intravenously  at  a  variable  rate  to  “clamp”  blood 
glucose  concentration   in  normal  range(euglucemic).  an 
infusion  of  potassium  phosphate  is  also  given  to  prevent 
hypokalemia  resulting  from hyperinsulinemia  and increased 
glucose disposal.the whole body glucose disposal at a given 
at  a  given  level  of  hyperinsulinemia  can  be  determined 
directly alternatively an insulin sensitivity index (S1) derived 
from clamp data can be defined as SI clamp=M/(G*∆I),where 
M  is  normalized  for  G(steady  state  blood  glucose 
concentration) and  ∆I (difference between fasting and steady 
state plasma insulin concentration) (Katz A et al. 2000).
Advantages:
The  main  advantage  of  using  glucose  clamp  to  estimate 
insulin sensitivity /resistance in humans is that it directly measures 
whole body glucose disposal at a given level of insulinemia under 
steady state conditions.
Limitations:
• Time consuming 
• Labor intensive
• Expensive
• It  requires  an  experienced  operator  to  manage  technical 
difficulties. Another limitation is that the clamp utilizes steady 
state insulin level that may be supraphysiological.
Insulin  Suppression  Test: This  is  a  another  method   that 
directly measures metabolic insulin sensitivity/ resistance, was 
introduced  by  Shen  et  al. (Shen  SW,   et  al. 1970)  and 
subsequently modified by Harano  et al. (  Harano Y,  et al. 
1978).  After  an  over  night  fast,  somatostatin  (250 µg/h)  is 
intravenously  infused  to  suppress  endogenous  secretion  of 
insulin and glucagon. Simultaneously insulin and glucose are 
infused  into  same  anticubital  vein  for  3h.  From the  contra 
lateral  arm,  blood  samples  for  glucose  and  insulin 
determination are taken at every 30mins for 2.5h and then at 
10mins  interval  from  150-180  mins  IST.  The  constant 
infusions of insulin and glucose will determined steady state 
plasma  insulin  (SSPI)  and  glucose  (SSPG)  concentrations. 
The steady state period is assumed to be from 150-180 mins 
after  initiation  of   IST.  SSPI  concentrations  are  generally 
similar  among  subjects.  Therefore,  the  SSPG concentration 
will  be  higher  in  insulin  resistance  subjects  and  lower  in 
insulin sensitive subjects; ie SSPG values are inversely related 
to  insulin  sensitivity.  The  IST  provides  a  direct  measure 
(SSPG) of the ability of exogenous insulin to mediate disposal 
of an intravenous glucose load under steady state conditions 
where endogenous insulin secretion is suppressed.
Advantage:
• The  SSPG  is  highly  reproducible  direct  measurement  of 
metabolic actions of insulin that is less labor intensive and less 
technically demanding than the glucose clamp.
• Estimates of insulin sensitivity determined by SSPG correlate 
well  with  reference  standard  glucose  clamp  estimates  in 
normal subjects and in patients with type 2 diabetes mellitus.
• More over,  the IST can be used for  larger populations that 
may  pose  difficulties  for  application  of  the  glucose  clamp 
(Yeni-Komshian H et al. 2000) .
Limitation
Many  of  the  limitations  of  the  IST  are  similar  to  those 
described  above for the glucose  clamp (with the exceptions that the 
IST is less technically demanding). Thus, it is impractical to apply 
the  IST  in  large  epidemiological  studies  or  in  the  clinical  care 
settings.
Indirect Measures of Insulin Sensitivity
Minimal model analysis of frequently sampled intravenous 
glucose tolerance test
Procedure and concept
The  minimal  model,  developed  by  (Bergman,  R  N  et  al. 
1979),  provides  an  indirect  measurement  of  metabolic  insulin 
sensitivity/  resistance  on  the  basis  of  glucose  and  insulin  data 
obtained during a frequently sampled intravenous glucose tolerance 
test. After an over night fast, an intravenous bolus glucose is infused 
over 2 mins starting at  time 0 currently,  a modified FSIVGTT is 
used where exogenous insulin is also infused over 5 mins beginning 
20 mins after the intravenous glucose bolus ( Quon M J et al. 2001). 
Blood  samples  are  taken  for  plasma  glucose  and  insulin 
measurement at 0-180 mins (10 mins interval). These data are then 
subjected  to  minimal  model  analysis  using the computer  program 
MINMOD to generate and index of insulin sensitivity(SI).
Advantage:
• Minimal model analysis of the modified FSIVGTT is easier 
than the glucose clamp method because it is slightly less labor 
intensive, steady state conditions are not required, and there 
are no intravenous infusion that require constant adjustment.
• The minimal model generates excellent prediction of  glucose 
disappearance during the FSIVGTT.
Limitations:
• It  still  involves  intravenous  infusions  with  multiple  blood 
sampling over a 3h period that are nearly as labor intensive as 
the glucose clamp or IST.
• The  over  simplification  of  the  minimal  model  involves 
lumping  together  effects  of  insulin  to  promote  peripheral 
glucose utilization suppress HGP.
Insulin  tolerance  test  (ITT).  A  simplified  version  of  IST,  ITT 
measures the decline in serum glucose after an IV bolus of regular 
insulin (0.1–0.5 U/kg) is administered. Several insulin and glucose 
levels are sampled over the following 15 minutes (depending on the 
protocol  used).  The  ITT  primarily  measures  insulin-stimulated 
uptake of glucose into skeletal muscle. Because this test is so brief, 
there's very little danger of counter-regulatory hormones interfering 
with its results. IV access should be established for insulin injection, 
blood sampling, and for rapid administration of D50W should severe 
hypoglycemia occur. Normal values for women with PCOS have not 
been published to date, but normal ranges for insulin sensitivity in a 
general  population  have  been  published  for  persons  with  a  body 
mass  index  below  30  kg/m2  and  for  obese  subjects  (BMI  >30 
kg/m2)  at  0.026  to  0.085  mmol/L  /minute  and  0.012  to  0.017 
mmol/L /minute respectively. These values reflect the rate of decline 
of log transformed glucose values.
Continuous  infusion  of  glucose  with  model  assessment 
(CIGMA). Like ITT, CIGMA requires fewer venipunctures and is 
less laborious than clamp techniques. A constant IV glucose infusion 
is administered, and samples for glucose and insulin are drawn at 50, 
55, and 60 minutes. A mathematical model is then used to calculate 
SI.  The results  are  reasonably  compatible  with clamp techniques; 
however, few laboratories have used CIGMA for insulin sensitivity 
testing in diabetic patients and there is no substantive data using the 
CIGMA technique in women with PCOS.
Oral Glucose Tolerance Test/ Meal Tolerance Test
The oral glucose tolerance test (OGTT) is a simple test widely 
used in clinical practice to diagnose glucose intolerance and type 2 
diabetes (American diabetes association 2007). After over night fast, 
blood  samples  for  determinations  of  glucose  and  insulin 
concentrations  are  taken  at  0,  30,60  and  120  mins  following  a 
standard oral glucose load (75 g) or a standard meal (Dalla Man C, 
et  al. 2005).  Oral  glucose  tolerance  reflects  the  efficiency  of  the 
body to dispose of glucose after an oral glucose load or meal. The 
OGTT or meal tolerance test mimics the glucose and dynamics of 
physiological conditions more closely than conditions of the glucose 
clamp, IST or FSIVGTT. In addition to metabolic actions of insulin, 
insulin  secretion,  incretin  effects,  and  other  factors  contribute 
importantly to glucose tolerance.
Table 7: Protocols: their attributes, and information content
Protocol Is It Physiological?
Is It 
Simple?
Can It 
Assess β-
Cell 
Function?
Can It 
Assess 
Insulin 
Sensitivity?
Can It 
Assess 
Hepatic 
Insulin 
Extraction?
Basal State Yes Yes Yes, but 
limited 
Yes, but 
limited 
No
Intravenous 
perturbation 
i) Hyperglycemic 
clamp
No No Yes, but 
limited 
without a 
model 
Yes, but 
requires a 
model
Yes, but 
requires a 
model.
ii) Euglycemic 
clamp
No No No Yes No
iii) IVGTT No No Yes, but 
limited 
without a 
model
Yes, but 
limited 
without a 
model
Yes, but 
requires a 
model.
iv) Graded 
infusion 
No No Yes, but 
limited 
without a 
model 
Yes, but 
requires a 
model.
Yes, but 
requires a 
model.
Oral perturbation 
i) OGTT
Yes, but no 
nutrients
Yes Yes, , but 
limited 
without a 
model
Yes, but 
requires a 
model.
Yes, but 
requires a 
model.
ii) Meal Yes Yes Yes,  but 
limited 
without a 
model
Yes, but 
requires a 
model.
Yes, but 
requires a 
model.
ORAL GLUCOSE TOLERANCE TEST:  The  oral  glucose 
tolerance  test  (OGTT)  has  traditionally  been  used  to  classify  the 
status of glucose tolerance for diagnostic purposes: normal glucose 
tolerance  (NGT)  versus  impaired  glucose  tolerance  (IGT)  versus 
diabetes  (WHO).  More  recently,  however,  some  authors  have 
attempted to exploit  the information contained in a 2-h OGTT to 
estimate insulin sensitivity (Mari A, et al. 2001) and ß-cell function . 
While the derived indexes are less accurate than the respective gold-
standard  methods,  they  can  be  obtained more  easily  and  used  in 
large epidemiological or genetic association studies. These indexes 
take advantage of glucose and insulin concentrations at specific time 
points  during  the  OGTT. the  glucose  curve  during  the  OGTT as 
“biphasic,” “domed,” and “upward” (Fuchigami M, et al. 1994). The 
main finding was that in patients with type 2 diabetes, the prevalence 
of biphasic was lower and the prevalence of upward was higher than 
in  any  other  group.  This  appears  somewhat  trivial,  because  the 
category upward naturally favors enrichment with diabetic subjects 
who, by definition, have the highest glucose concentrations at the 
end  of  the  OGTT.  Nevertheless,  it  is  interesting  to  note  that  the 
biphasic shape was most strongly associated with NGT in that study. 
This  suggests  that  the  shape  harbors  metabolic  information  not 
captured by the level of glycemia alone.
Definition  of  monophasic  and  biphasic  plasma  glucose  curve 
shapes:
 The glucose  curve  shape  of  an  OGTT  was  classified  as 
“monophasic”  when  plasma  glucose  increased  after  an  oral 
glucose load to the maximum after 30–90 min and decreased 
until  120 min with a final  downward move of at least 0.25 
mmol/l between 90 and 120 min.
 Glucose shapes that reached a nadir after an initial increase 
and  increased  again   >0.25  mmol/l  until  120  min  were 
classified as “biphasic”
 The shape index,  calculated as  glucose at  90 min (Gluc90) 
minus  glucose  at  120  min  (Gluc120)  was  treated  as  a 
continuous variable in correlational analyses. A shape index 
>0  indicates  biphasic  and  a  shape  index  <  0  indicates 
monophasic.
 In subjects showing a decrease of plasma glucose between 30 
and  60  min,  an  increase  between  60  and  90  min,  and  a 
decrease again between 90 and 120 min (i.e.,  two complete 
peaks or a “triphasic” shape), the increase between 60 and 90 
min was taken as shape index to avoid false classification of 
these  subjects  as  monophasic.  One  IGT  subject  with  a 
continuous increase during the 120 min was excluded.
LITERATURE SURVEY
R S Scott  et  al.,  (2009)  made  a  study  on “comparison  of 
indices  of  insulin  resistance  with  metabolic  syndrome 
classifications  to  predict  the  development  of  impaired  fasting 
glucose in over weight and obese subjects: a 3- year prospective 
study”. The study was done to compare the ability of biochemical 
indices  of  insulin  resistance  (ir)  with metabolic  syndrome (MetS) 
classifications to predict changes in blood glucose control over a 3-
year period in over weight and obese subjects. The study concluded 
that IR indices derived from plasma triglyceride concentration, were 
sensitive  predictors  for  the  development  of  IFG  risk  group  in 
normoglycemic overweight and obese subjects and indices derived 
from glucose and insulin did not identify at this group. this study 
also  showed  that  presence  of  MetS  and  its  abnormalities  of  an 
increased trig:HDL ratio and low plasma adiponectin concentration 
were all sensitive predictors of IFG.
Maffeis Claudio et al., (2009) performed a study on “Fasting 
plasma glucose (FPG) and the risk of impaired glucose tolerance 
in obese children and adolescents.” The study was done to assess 
whether  one  or  more  biochemical  indexes  measured  in  fasting 
conditions  could  be  used  to  identify  obese  children  at  risk  of 
IGT.this study was carried out in 563 obese children and adolescents 
(M/F  -315/248;  aged  4-17  years)was  recruited  and  underwent 
anthropometric  evaluation  and  OGTT.Anthropometric  parameters, 
fasting  plasma  glucose(FPG),fasting  serum  insulin(FSI),and 
homeostatic  model  assessment  of  insulin  resistance  (HOMA-IR) 
were  tested  in  pursuit  of  a  possible  threshold  to  be  used  as  a 
predictor of IGT.Results shown was that the three parameter did not 
show  significantly  different  sensitivity/specificity  in  the  pooled 
population or in the gender /puberty subgroups. In this study they 
concluded that a gender/puberty independent cut off of FPG may be 
considered as screening tool to narrow clinical indication to OGTT 
in obese white children and adolescents.
Malita  FM  et  al.,  (2009)  done  a   study  on  “comparison 
between  several  insulin  sensitivity  indices  and  metabolic  risk 
factors  in  overweight  and  obese  postmenopausal  women-A 
MONET study.” The  purpose  of  this  study  was  to  compare  the 
relationship  of  several  insulin  sensitivity  indices  with 
cardiometabolic  risk  factors  in  overweight  and  obese 
postmenopausal  women.  They  concluded  that  the  present  study 
indicates that the different methods of measuring and/or expressing 
insulin  sensitivity  display  variations  for  associations  with 
cardiometabolic  risk  factors.  Therefore  interpretations  of  relation 
ships  between  insulin  sensitivity  indices  and  cardiometabolic  risk 
factors  should take into account the method used to estimate and 
express insulin sensitivity.
Jens J. Holst et al., (2009) made a study on “Natural history 
of  insulin  sensitivity  and  insulin  secretion  in  the  progression 
from normal glucose tolerance to impaired fasting glycemia and 
impaired  glucose  tolerance:  the  inter99  study”  the  aim  of  the 
study was to  describe the natural  history of  insulin  secretion and 
insulin  sensitivity  in  the  development  of  impaired  fasting 
glycemia(IFG),impaired  glucose  tolerance(IGT),and  combined 
IFG/IGT. in this study baseline and 5-year follow up data from the 
Inter 99 study were used.individuals with normal glucose tolerance 
(NGT) at baseline and IFG and IGT ,combined IFG/IGT, or NGT at 
the 5-year follow up were examined with an ogtt . Insulin sensitivity 
index(ISI),HOMA-IS, early phase insulin release (EPIR),and insulin 
secretion  relative  to  insulin  action  (disposition  index)  were 
estimated. The conclusion of this study is that there is a stationary 
reduced  insulin  secretion  followed  by  decline  in  hepatic  insulin 
sensitivity  characterizes  transition  from NGT-IFG.in  case  of  IGT 
there is low whole body insulin sensitivity with a secondary lack of 
ß-cell  function.  Thereby  both  IFG  and  IGT  have  different 
mechanisms which will be useful for the prevention and treatment of 
the diabetes that succeeds them.  
K.Faerch  et  al., (2009)  attempted   a  study  on 
“Pathophysiology and aetiology of impaired fasting glycemia and 
impaired glucose  tolerance: does it  matter for prevention and 
treatment  of  type2  diabetes.”the  aim  of   the  study   was  to 
understand  the  aetiology  and  pathophysiology  of  the  prediabetic 
states  might  give  a  basis  for  the  development  of  individualized 
prevention and treatment strategies for type 2 diabetes. Prediabetic 
stages are IFG, IGT, combined IFG/IGT. These stages have different 
pathophysiology and aetiology. So in this study they concluded that 
the transition from the prediabetic states to overt type 2 diabetes is 
characterized by a non –reversible vicious cycle that include severe 
delitorius effects on glucose metabolism, there are good reasons to 
use  the  well  established  aetiological  and  pathophysiological 
differences  in  IFG,  IGT  and  IFG/IGT  to  design  individualized 
preventive strategies.
 
A.Vaag  et  al., (2008)  done  a  study  on  “Impaired  fasting 
glycemia  vs  impaired  glucose  tolerance:similar  impairment  of 
pancreatic alpha and beta cell function but differential roles of 
incretin  hormones  and  insulin  action.”  The  hypothesis  of  the 
study was to prevent type 2 diabetes in impaired fasting glycemia 
(IFG) vs impaired glucose tolerance (IGT) may differ depending on 
the  underlying  pathophysiology.  They  evaluated  insulin  secretion 
during OGTTs and IVGTTs, hepatic and pheripheral insulin action 
and glucagon and incretin hormone secretion in individuals with IFG 
and IGT and NGT (normal  glucose  tolerance)finally  in  the  study 
they  concluded  that  differentiated  preventive  initiatives  in 
prediabetic individuals should be tested, targeting the specific above 
mentioned metabolic defects.
M.Lassko et al., (2008) done a study on “Insulin sensitivity, 
insulin release and glucagon-like peptide-1 levels in persons with 
impaired  fasting glucose  and/or  impaired glucose  tolerance in 
the EUGENE2 study.” the aim of the study was to examine the 
phenotype of the individual impaired fasting glucose (IFG) and/or 
impaired glucose tolerance(IGT) with regard to insulin release and 
insulin  resistance.  In  their  study  they took non diabetic  offspring 
(n=874;mean age 40±10.4 years; BMI 26.6±4.9 kg/m2 ) of type 2 
diabetic  patients  from different  European  centers  were  examined 
with insulin sensitivity(euglycemic clamp),insulin release (IVGTT) 
and  glucose  tolerance  (OGTT)levels  of  glucagon  like  peptide-
1(GLP-1) and gastric inhibitory polypeptide (GIP) were measured 
during ogtt.  They   conclude   that  primary  mechanism leading to 
hyperglycemia in participants with IFG is likely to be impaired basal 
and  first  –phase  insulin  secretion,  whereas  in  IGT  the  primary 
mechanism  leading  to  post  glucose  hyperglycemia  is  insulin 
resistance  reduced  GLP-1  levels  were  seen  in  all  groups  with 
abnormal glucose tolerance and were unrelated to the insulin release 
pattern during an IVGTT.
Ranganath  Muniyappa  et  al.,  (2007)  made  a  study  on 
“Current  approaches  for  assessing  insulin  sensitivity  and 
resistance  in  vivo:  advantages,  limitations  and  appropriate 
usage.” the aim of this study was to highlight merits, limitations and 
appropriate  use  of  current  invivo  measures  of  insulin 
sensitivity/insulin  resistance.  quantifying  insulin  resistance/ 
sensitivity in humans and animal models is of great  importance for 
epidemiological  studies.  There  are  several  direct  and  indirect 
methods  for  assessing  insulin  sensitivity/resistance.  But  these 
methods are labor intensive, time consuming. And it is important to 
understand  the  concepts  underlying  each  method  so  that  relative 
merits  and  limitations  are  appropriately  matched  to  proposed 
applications.  And  they  concluded  the  study  by  regarding  simple 
surrogates,  QUICKI  and  log  (HOMA)  are  among  best  and  most 
extensively validated.
James D  Johnson et al., (2007) made a study on “pancreatic 
apoptosis in maturity onset diabetes of the young.” maturity onset 
diabetes (MODY) denotes a group of disorders characterized by an 
autosomal dominant mode of inheritance. Mody presents in children, 
adolescents,  or  young  adults  and  may  account  for  up  to  5%  of 
diabetes cases. Gene mutated in mody include 5 transcription factor 
and metabolic enzyme glucokinase ; apart from their involvement in 
the function of pancreatic beta cells, these genes also have several 
unexpected common ties. The aim of this study was evidence from 
recent studies that suggests important roles for mody genes in the 
control of beta cell metabolic pathways and cell fate. From this study 
they  concluded  that  investigation  in  to  the  pathophysiology  of 
diabetes have been guided by the discovery of genes associated with 
the disease. The study have also suggested that mutation in HNF-
1alpha, HNF-4alpha or PDX-1 may predispose certain populations 
to late onset type2 diabetes. The evidence is that mutation in mody 
genes play a dominant  role in the most  common forms of type 2 
diabetes is lacking.
Mehtap  Cakir  et  al., (2006)  made  a  study  on 
“Reproducibility  of  fasting and ogtt-derived insulin  resistance 
indices in normoglycemic women”  the aim of this study was to 
determine the reproducibility of fasting and oral glucose tolerance 
test (ogtt) – derived insulin resistance (IR) indices in obese and non 
obese  women  in  this  study  they  used  twenty  one  obese  (BMI 
37.7±6.3  kg/m)  and  non  obese  (BMI  21.5±1.0kg/m)age-matched, 
healthy, premenopausal women were included in the study. An ogtt 
was performed twice, with a 1-week interval between tests.IR was 
also calculated from fasting and post load glucose and insulin values, 
using some of the more well-known indices. In this they concluded 
that  when two groups were  evaluated  separately  all  indices  were 
reproducible  in  obese  subjects  ,but  some  indices  were  not 
reproducible  in  non  obese  healthy  controls.  When  results  were 
analyzed  in  the  study  population  as  a  whole,  all  indices  were 
reproducible.
Supamai Soonthurnpun et al., (2003) done a study on “Novel 
insulin sensitivity derived from oral glucose tolerance test”  the 
euglycemic  hyperglycemic  clamp  is  generally  regarded  as  a 
reference  method  for  assessing  insulin  sensitivity.  However  this 
method is laborious and expensive. The oral glucose tolerance, the 
most  commonly  used  method  for  evaluating  whole  body  glucose 
tolerance and insulin sensitivity. in the previous study the correlation 
between  ISI(ogtt)  and   ISIclamp  may  not  be  satisfactory.this  is 
because  ISIclamp  is  designed  for  measuring  pheripher  al  glucose 
utilization, whereas plasma glucose responses during ogtt are results 
pheripheral glucose utilization and hepatic glucose production based 
on this problem they developed an equation of ISI(ogtt). They tested 
with healthy volunteers  and finally  they concluded that  ISI (ogtt) 
derived from their equation is more suitable than other for assessing 
insulin sensitivity in subjects with normal glucose tolerance.
Zofia Cervenakova  et al.,(2002) done a study on  “Effect of 
body composition on indices of insulin sensitivity and beta-cell 
function in healthy men” the aim of this study was to evaluate the 
influence  of  body  composition  on  various  indices  of  insulin 
sensitivity and secretion in subjects with normal glucose tolerance. 
A total of 33 male subjects (aged 26-51 years,BMI19.7-30.9kg/m2  ) 
underwent  a  standard  oral  glucose  tolerance  tests  and  they  were 
measured using indices of insulin sensitivity and the results showed 
that all subjects had a normal glucose tolerance no difference was 
found in course of  glycemia,  while  over  weight subjects  had an 
enhanced  insulin  response.  The  indices  of  insulin  sensitivity  all 
significantly  increased  in  overweight  group.  And  finally  they 
concluded  this  study  is  that  easiest  way  of  predicting  insulin 
resistance in normal glucose tolerance is to calculate an index from 
glucose and insulin concentration during an ogtt.
M.Albareda et al., (2000) “Assessment of insulin sensitivity 
and beta cell  function from measurements  in the fasting state 
and during an oral glucose tolerance test”  the aim of the study 
was to find if the relation between insulin sensitivity and beta cell 
function  assessed  from  fasting  and  ogtt  measurements  has  a 
physiological shape. The study was performed  with healthy women 
without diabetic first degree relatives underwent a 75g ogtt with a 
plasma glucose and insulin (n=35) concentration being measured at 
(0,30,60  and  120)  beta  cell  function  and  insulin  sensitivity  were 
measured using indices. A hyperbolic relation was tested for 21 beta 
cell  function insulin sensitivity pairs using a non-lineal regression 
method. Finally they conclude the study by the estimation of insulin 
sensitivity and beta cell function by most using method ogtt did not 
adjust to hyperbolic relation in healthy women but fasting indices 
combination did and beta cell function estimated the HOMA index 
and insulin sensitivity with fasting glucose to insulin ratio had the 
best adjustment.
Michael Stumvoll et al., (2000) made a study on “Use of oral 
glucose  tolerance  test  to  assess  insulin  release  and  insulin 
sensitivity ”the aim of this study was that the oral glucose tolerance 
test has been often been used to evaluate apparent insulin release and 
insulin resistance in variable clinical settings. They studied with non 
diabetic  volunteers  who  had  undergone  ogtt  and  euglycemic 
hyperinsulinemic clamp for assessing insulin sensitivity and insulin 
release.  Demographic  parameters  and  plasma  glucose  and  insulin 
values  from  ogtt  were  subjected  to  multiple  linear  regression  to 
predict metabolic clearance rate of glucose, the ISI and Ist phase and 
2nd phase insulin release as measured with respective clamps. Finally 
they  concluded  this  study  that  predicting  insulin  sensitivity  and 
insulin release with reasonable accuracy from simple demographic 
parameters  obtained  during  ogtt  is  possible.the  derived  equation 
would be impractical in various clinical setting. 
D.Tripathy et al., (2000) made a study on “Insulin secretion 
and  insulin  sensitivity  in  diabetic  subgroups:  studies  in  the 
prediabetic  and  diabetic  state”  the  aim  of  this  study  was  to 
evaluate insulin sensitivity and insulin secretion in prediabetic and 
diabetic  subjects  with  mutation  in  mody1  and  mody3  genes,  in 
subjects with GAD antibodies ,latent autoimmune diabetes in adults 
and in subjects with the common form of type II diabetic mellitus. 
Insulin secretion was measured as the incremental 30min insulin and 
insulin  glucose  ratio  during  ogtt  and  also  insulin  sensitivity  was 
measured as insulin sensitivity index in all types of diabetic patients 
and  also  these  subgroup  subjects  underwent  a  euglycemic  clamp 
intravenous  glucose  tolerance  test  for  estimation  of  insulin 
sensitivity and first phase insulin secretion. Finally they concluded 
the study by that glucose tolerance carriers of mody mutation are 
characterized by severe impairment in insulin secretion. Enhanced 
insulin sensitivity seen in normal glucose tolerance. In subjects with 
positive  GADA or  type2 have  impaired  insulin  sensitivity.  mody 
mutation carriers were protected from the effect of glucose toxicity.  
 
  
   
 
METHODOLOGY
OGTT
Fasting  glucose load (75g)
      
(Done at 8.30 a.m after 10-12 hrs (Done after half-an-
hour  overnight fasting)            from fasting)
                            
Blood  collection by                   Blood collection 
by finger prick method                                            finger prick 
method
                                                                                   
Collection of blood                                 Sample collection of blood  
at  sample  at  0  min 
30,  60,  90,  120  min 
respectively
Blood glucose monitoring    
                                                                                   
      Blood glucose monitoring
       
PRINCIPLE FOR INSULIN ASSAY
The Insulin Quantitative Test  Kit is based on a solid phase 
enzyme-linked immunosorbent assay. The assay system utilizes one 
anti-Insulin  antibody  for  solid  phase  (microtiter  wells) 
immobilization  and another  anti-Insulin  antibody in  the  antibody-
enzyme (horseradish peroxidase) conjugate solution. The standards 
and test specimen (serum) are added to the Insulin antibody coated 
microtiter  wells.  Then  anti-  Insulin  antibody  labeled  with 
horseradish  peroxidase  (conjugate)  is  added.  If  human  Insulin  is 
present in the specimen, it will combine with the antibody on the 
well  and the enzyme conjugate  resulting in  the Insulin molecules 
being  sandwiched  between  the  solid  phase  and  enzyme-linked 
antibodies. After a 1 hour incubation at room temperature, the wells 
are  washed  with  water  to  remove  unbound labeled  antibodies.  A 
solution  of  chemiluminescent  substrate  is  then  added  and  read 
relative light units (RLU) in a Lumino meters. The intensity of the 
emitting light is proportional to the amount of enzyme present and is 
directly  related  to  the  amount  of  INSULIN  in  the  sample.  By 
reference to a series of INSULIN standards assayed in the same way, 
the concentration of INSULIN in the unknown sample is quantified.
MATERIALS 
• Xylene-manufactured by fischer chemic ltd.,
• Sterile   Absorbent  Cotton-manufactured  by  The  Ramaraju 
Surgical Cotton Mills Ltd.,
• Sterile blood lancets-manufactured by Medipoint, Inc.,
• Blood glucose test strips- manufactured by Major Biosystem 
Corp. 
• Glucose-D-(1 kg)-manufactured by Avalon Cosm. Pvt. Ltd.,
• Centrifuge tubes (1 ml)- Eppendorf Ltd.,
• Disposable syringe (5 ml)-BD
• Vaccum  blood  collection  tube  (5ml)-  manufactured  by 
peerless biotech private ltd.,
• Disposable filler-BD
• Precision pipettes and tips, 0.05 ml, 0.1 ml – Tarsons Products 
Pvt. Ltd.,
• Disposable pipette tips- Himedia
• Distilled water
• Absorbent paper 
• Microtiter plate reader- Tarsons Products Pvt. Ltd.,
• Monoclonal anti Insulin antibody coated microtiter plate with 
96 wells.
• Enzyme conjugate reagent, 12 ml.
• Insulin reference standards containing; 0, 5, 25, 50, 100, and 
200 uIU/ml. lyophilized 0.5mlx2sets.
• Wash Solution Concentrate, 50X, 15ml
• Chemiluminescence Reagent A, 6.0 ml.
• Chemiluminescence Reagent B, 6.0 ml.
REAGENTS FOR INSULIN ASSAY
1. All  reagents  were  kept  at  room temperature  (18-25°C)  and 
mixed gently by inverting or  swirling without  formation of 
foam.
2. 1 volume of Wash Buffer (50x) was diluted with 49 volumes 
of distilled water
3. Each lyophilized standard was reconstituted with 0.5 ml  of 
distilled water and was allowed to stand for 20 minutes.
INSTRUMENT:
OGTT - Gluco Chek blood glucose monitoring 
system- manufactured by Major Biosystem 
Corp Taiwan
INSULIN ASSAY - Immulite 2000
Vortex mixer - Remi Motors Ltd.,
Centrifuge              -         Eppendorf Ltd.,
METHODOLOGY
I.  OGTT
Currently two methods are available:
a.  Traditional Method- Finger Prick Method
b.  Glucose Oxidase Method
a.  TRADITIONAL METHOD
Blood  glucose  meter  is  a  small  portable  machine  used  to 
monitor blood glucose levels.
PROCEDURE
1. Hands  were  washed  in  warm,  soapy  water  and  dried 
thoroughly.
2. Finger tip was cleansed using sterile cotton soaked in spirit
3. The finger was then allowed to dry.
4. The test strip was inserted into the slot of the glucose meter 
with the black bars of the test strip facing up.
5. Fingertip  was  pricked  using  a  sterile  lancet  and  gently 
squeezed to get a drop of blood.
6. The  blood  drop  was  placed  on  the  test  strip,  previously 
inserted  into  the  glucose  meter  and  monitored  for  blood 
glucose levels.
7. The glucose meter soon displays the blood glucose level as a 
number in mg/dl unit.
INSULIN ASSAY
PROCEDURE FOR SERUM COLLECTION
1. A  tourniquet  was  placed  around  the  upper  arm  to  apply 
pressure and cause the veins to swell with blood.
2. Blood was drawn from a vein in the arm inside of the elbow 
after cleaning the skin surface with an antiseptic and collected 
in a syringe.
3. The blood was then collected in a plain red-top venipuncture 
tube without additives.
4. The blood was then allowed to clot.
5. The specimen was then centrifuged to separate the serum from 
cells.
INSULIN ASSAY PROCEDURE
1. Desired number of coated wells was secured in the holder. 50μl 
of Insulin standards, specimens, and controls were added into 
the appropriate wells and mixed gently for 10 seconds.
2. 100μl of enzyme conjugate reagent was added into each well 
and mixed gently for 30 seconds to facilitate complete mixing 
and incubated at room temperature for 60 minutes.
3. The incubation mixture  was then removed and the microtiter 
plate was rinsed 5 times with 1 x wash buffer (300μl each well). 
Then the residual water droplets were removed using absorbent 
paper.
4. 100 μl Chemiluminescence substrate solution was then added 
into each well and gently mixed for 5 seconds.
5. After  5  minutes,  the  wells  were  observed  using  a 
chemiluminescence microwell reader. 
Methodology for AUC calculation
Total AUCs for glucose and insulin were calculated using the 
trapezoidal rule.
Methodology for cluster analysis
Data often fall naturally into groups / clusters, of observations, 
where the characteristics of objects in the same cluster are similar.
K-means clustering (partitioning) treats observations in the data as 
objects having locations and distances from each other. It partitions 
the  objects  into  K  mutually  exclusive  clusters,  such  that  objects 
within each cluster are as close to each other as possible, and as far 
from  objects  in  other  clusters  as  possible.  Each  cluster  is 
characterized by its centroid (center point). Of course, the distances 
used  in  clustering  often  do  not  represent  spatial  distances. 
Hierarchical  clustering  investigates  grouping  in  the  data, 
simultaneously over a variety of scales of distance,  by creating a 
cluster tree. The tree is not a single set of clusters, as in K-Means, 
but  rather  a multi-level  hierarchy,  where clusters  at  one level  are 
joined as clusters at the next higher level. This allows us to decide 
what  scale  or  level  of  clustering  is  most  appropriate  in  our 
application.
Variables  were  analyzed  by  a  computer  program  which 
permits  direct  visualization  of  the three dimensional  shape of  the 
data set  and the subjects  were classified by means of a computer 
classification  which  employed  a  cluster  analysis  technique.  This 
resulted in the definition of three groups.
Methodology for calculating HOMA-IR
Homeostasis  model  assessments  of  insulin  resistance 
(HOMA2-IR) and pancreatic beta-cell function (HOMA2-%B) were 
completed  using  the  HOMA  Calculator  version  2.2.2 
(http://www.dtu.ox.ac.uk, accessed Feb 2010).
INDICES CALCULATION
 The indices evaluated were selected  a priori  based on their 
performance in previous investigations.The insulin sensitivity index 
(ISI) was calculated from the oral glucose tolerance test according to 
the formula: 
ISI = 10,000 ÷ √ ([fasting plasma glucose × fasting plasma insulin] × 
[mean OGTT glucose × mean OGTT insulin]). 
Beta-cell  function was  assessed  as  corrected  incremental 
insulin response (CIR) during the glucose-tolerance test according to 
the formula: 
CIR = (100 × insulin at 30 min) ÷ ([glucose at 30 min] × [glucose at 
30 min − 3.89]) 
(or)  as a disposition index (i.e., insulin secretion adjusted for insulin 
sensitivity, or CIR × ISI).
RESULTS
Table 8: OGTT Glucose Concentrations in mg/dL
Status code 0min 30min 60min 90min 120min
FH 122 78 159 178 148 125
FH 121 75 161 176 148 129
FH 171 81 166 176 119 70
FH 172 83 151 175 119 75
FH 71 104 118 159 116 103
FH 72 105 133 154 138 89
FH 181 103 156 147 110 98
FH 21 98 110 140 129 88
 131 81 115 139 126 79
 14 65 133 134 109 74
 19 98 147 132 114 100
52 94 137 124 104 95
1 77 133 124 93 82
16 109 137 123 109 98
4 87 147 122 111 84
10 91 131 119 96 105
9 81 141 118 96 85
15 88 131 117 102 89
82 94 156 115 100 93
132 87 128 115 97 107
3 88 131 115 91 84
20 80 137 114 105 96
11 97 136 113 100 68
62 90 133 112 70 93
2 59 135 111 86 77
182 101 133 111 111 98
61 93 104 98 60 94
51 94 131 84 75 83
81 91 96 68 70 89
Fig1: OGTT CURVE
OGTT CURVES
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Fig 2: OGTT curve for Subjects without Family 
history of Diabetes
Fig 3: OGTT (NGR group) -3rd order polynomial fit
OGTT (NGR Gr) - 3rd Order Polynomial Fit
y = 6x3 - 61.896x2 + 185.57x - 38.446
R2 = 0.9625
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Fig 4 :OGTT (IGR group)-3rd order polynomial fit
OGTT (IGR Gr) - 3rd Order Polynomial Fit
y = 3.0682x3 - 42.828x2 + 163.19x - 35.891
R2 = 0.9891
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Fig 5: OGTT insulin group
Fig6: Cluster analysis of OGTT blood glucose concentrations
Cluster Frequency
1 7
2 3
3 19
Variable Total std Within std R-square Rsq/(1-rsq)
30min
60min
90min
OVER-ALL
16.48899
26.87602
21.45370
22.01869
12.98106
10.66505
13.79622
12.55106
0.424497
0.853778
0.616000
0.698288
0.737609
5.838931
1.604167
2.314416
Table 9:  Cluster Analysis for All Subjects
OBS CODE CLUSTER
1 1 3
2 2 3
3 3 3
4 4 3
5 51 2
6 52 3
7 61 2
8 62 3
9 71 1
10 72 1
11 81 2
12 82 3
13 9 3
14 10 3
15 11 3
16 121 1
17 122 1
18 131 3
19 132 3
20 14 3
21 15 3
22 16 3
23 171 1
24 172 1
25 181 1
26 182 3
27 19 3
28 20 3
29 21 3
Fig 7: OGTT -60min curve for all subjects
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Fig :9 Correlation of AUCg with 1hr OGTT glucose
Correlation of AUCg with 1hr OGTT Glucose
y = 62.151x + 5803.3
R2 = 0.8741
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Fig:10 Correlation of AUCg  with 1hr OGTT glucose 
(NGR group)
Correlation of AUCg with 1hr OGTT Glucose (NGR Gr)
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Fig:11 Correlation  of AUCg with 1hr OGTT glucose 
(IGR group)
Correlation of AUCg with 1hr OGTT Glucose (IGR Gr)
y = 65.069x + 5254.3
R2 = 0.7348
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Table 10: AUCg Calculations for all the subjects
Case ID Time Interval First Last Minimum Maximum AUC (baseline = 0)
1 120 77 82 77 133 12885.0000
2 120 59 77 59 135 12000.0000
3 120 88 84 84 131 12690.0000
4 120 87 84 84 147 13965.0000
51 120 94 83 75 131 11355.0000
52 120 94 95 94 137 13785.0000
61 120 93 94 60 104 10665.0000
62 120 90 93 70 133 12195.0000
71 120 104 103 103 159 14895.0000
72 120 105 89 89 154 15660.0000
81 120 91 89 68 96 9720.0000
82 120 94 93 93 156 13935.0000
9 120 81 85 81 141 13140.0000
10 120 91 105 91 131 13320.0000
11 120 97 68 68 136 12945.0000
121 120 75 129 75 176 17610.0000
122 120 78 125 78 178 17595.0000
131 120 81 79 79 139 13800.0000
132 120 87 107 87 128 13110.0000
14 120 65 74 65 134 13365.0000
15 120 88 89 88 131 13155.0000
16 120 109 98 98 137 14175.0000
171 120 81 70 70 176 16095.0000
172 120 83 75 75 175 15720.0000
181 120 103 98 98 156 15405.0000
182 120 101 98 98 133 13635.0000
19 120 98 100 98 147 14760.0000
20 120 80 96 80 137 13320.0000
21 120 98 88 88 140 14160.0000
Group n AUC Mean 95% CI SD
AUC 
Median 95% CI
(All cases) 29 13760.690 13081.109 
To 14440.271
1786.586 13635.000 13132.978 to 
14163.511
Table 11: Cluster analysis of AUCg Values
OBS CASE ID CLUSTER
1 121 1
2 122 1
3 171 1
4 172 3
5 72 3
6 181 3
7 71 3
8 19 3
9 16 3
10 21 3
11 4 3
12 82 3
13 131 3
14 52 3
15 182 3
16 14 3
17 10 3
18 20 3
19 15 3
20 9 3
21 132 3
22 11 3
23 1 3
24 3 2
25 62 2
26 2 2
27 51 2
28 61 2
29 81 2
 
  Cluster Frequency
1 3
2 6
3 20
      
Variable Total std Within std R-Square RSQ/(1-RSQ)
AUC
OVER-ALL
1787
1787
935.78127
935.78127
0.745249
0.745249
2.925398
2.925398
             
Fig:12. AUCg plot for IGR group
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Group n Mean 95% CI SD Median 95% CI
(All cases) 11 15369.545
14437.48
6
to
16301.60
5
1387.38
7 15405.000
14095.310 
to
16364.540
Table 12:  AUCg calculation for IGR group
  
Case ID Time Interval First Last Minimum Maximum AUC (baseline = 0)
122 120 78 125 78 178 17595.0000
121 120 75 129 75 176 17610.0000
171 120 81 70 70 176 16095.0000
172 120 83 75 75 175 15720.0000
71 120 104 103 103 159 14895.0000
72 120 105 89 89 154 15660.0000
181 120 103 98 98 156 15405.0000
21 120 98 88 88 140 14160.0000
131 120 81 79 79 139 13800.0000
14 120 65 74 65 134 13365.0000
19 120 98 100 98 147 14760.0000
Fig:13. AUCg plot for NGR group
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Group n Mean 95% CI SD Median 95% CI
(All
 cases) 15 13217.000
12869.266 to
 13564.734 627.927 13155.000
12900.895 to 
13745.262
Table 13: AUCg calculation for NGR group
  
Case
ID
Time 
Interval First Last Minimum Maximum
AUC 
(baseline = 0)
52 120 94 95 94 137 13785.0000
1 120 77 82 77 133 12885.0000
16 120 109 98 98 137 14175.0000
4 120 87 84 84 147 13965.0000
10 120 91 105 91 131 13320.0000
9 120 81 85 81 141 13140.0000
15 120 88 89 88 131 13155.0000
82 120 94 93 93 156 13935.0000
132 120 87 107 87 128 13110.0000
3 120 88 84 84 131 12690.0000
20 120 80 96 80 137 13320.0000
11 120 97 68 68 136 12945.0000
62 120 90 93 70 133 12195.0000
2 120 59 77 59 135 12000.0000
182 120 101 98 98 133 13635.0000
Fig 14: AUCg plot for Low Sugar Group
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Group n Mean 95% CI SD Median 95% CI
(All cases
) 3 10580.000
8541.001 
to
12618.999
820.808 10665.000  
Table 14:  AUCg calculation for low sugar group 
  
Case I
D
Time
Interval First Last Minimum Maximum
Area under curve
(baseline = 0)
61 120 93 94 60 104 10665.0000
51 120 94 83 75 131 11355.0000
81 120 91 89 68 96 9720.0000
Table 15: OGTT Insulin values for selected individuals
Status Code Ins 0MIN
Ins 
30MIN
Ins 
120MIN 0min 30min 60min 90min 120min
4 6.8 4.4 1 87 147 122 111 84
2 6.4 53.6 12.5 59 135 111 86 77
51 3.7 66.7 2.2 94 131 84 75 83
62 3.1 17.2 2.8 90 133 112 70 93
81 53.4 91 96 68 70 89
131 52.6 81 115 139 126 79
FH 71 33.2 104 118 159 116 103
FH 181 29 103 156 147 110 98
Fig15. OGTT Insulin Plot for selected individuals
Fig:16. AUCg plot for selected individuals
0 20 40 60 80 100 120
140
120
100
80
60
40
20
0
Time
va
lu
es
Group n Mean 95% CI SD Median 95% CI
(All cases
) 3 11850.000
10757.897
to 12942.103 439.631 12000.000
Table 16: AUCg  calculation for OGTT insulin selected 
individuals
  
Case 
ID
Time 
Interval First Last Minimum Maximum
AUC Glucose
 (baseline = 0)
2 120 59 77 59 135 12000.0000
51 120 94 83 75 131 11355.0000
62 120 90 93 70 133 12195.0000
Fig:17. AUC Insulin for selected individuals
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Group n Mean 95% CI SD Median 95% CI
(All cases
) 3 12000.000
9653.081
to 14346.919 944.762 11865.000
  
Table 17: 
AUC insulin calculation
  
Case I
D Time Interval First Last Minimum Maximum
AUC Insulin
 (baseline = 0)
2 120 93 94 93 104 11865.0000
51 120 94 83 83 131 13005.0000
62 120 91 89 89 96 11130.0000
Fig:18. Clustering with 30 min Insulin & 60 min Glucose
Table:18 Cluster analysis for insulin performed subjects
OBS code CLUSTER
1
2
3
4
5
6
7
8
4
2
51
62
81
131
71
181
1
2
3
1
3
2
2
2
       
Cluster Frequency
1 2
2 4
3 2
Variable Total std Within Std R-Square RSQ/(1-RSQ)
INS 30 MIN 21.30848 11.52115 0.791186 3.788957
GLU 60 
MIN 
OVER ALL
30.98271
26.58928
16.88787
14.45574
0.7877782
0.78875
3.712132
3.736531
  
Table:19 Clustering ONLY WITH GLUCOSE 60 MINUTES
Cluster Frequency
1 3
2 2
3 3
Variable Totalstd
Within
std R-square
RSQ/
(1-RSQ)
GLU 60  MIN 30.98271 8.99630 0.939777 15.605025
OVER ALL 30.98271 8.99630 0.939777 15.605025
 
Fig: 19. 30MIN INSULIN VS 30 MIN GLUCOSE
Fig:20. 30 MINUTES INSULIN VS 60MINUTES GLUCOSE:  
Table 20:  Indices Calculation
COD
E
Glucose 
0min
Insulin
 0min
HOMA2 
%B
HOMA2 
%S
HOMA2 
IR
2 59 6.4 197.6 136.0 0.7
51 94 3.7 53.3 204.2 0.5
62 90 3.1 51.8 246.2 0.4
Table 21: Insulin 30 min Group - Indices
Code Glucose 30min
Insulin 
30min
HOMA2 
%B
HOMA2 
%S
HOMA2 
IR
2 135 53.6 175.5 14.2 7.0
51 131 66.7 - - -
62 133 17.2 78.2 41.6 2.4
81 96 53.4 316.4 15.4 6.5
131 115 52.6 227.1 15 6.7
71 118 33.2 156.1 22.8 4.4
181 156 29 86.6 24.4 4.1
Fig:21. Hyperbolic Curve Relationship
Insulin Response - hyperbolic Curve
y = 4464.3x-1.1134
R2 = 0.7188
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Fig:22. Early Phase Insulin Secretion
B Cell Function Vs 1st Phase Insulin Secretion
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Fig:23 & 24. OGTT Curves Showing high glucose values at 
60min discriminating pre-diabetes subtypes

Table 22: Comparision of different cluster analysis routines
S.
No Level
Subjects 
(AUCg)
Subjects
(G60)
Cluster
(Cluster)
1 Very High 121, 122 121, 122, 171, 
172
2 High 171, 172, 71, 
72, 181, 19
71, 72, 181, 
21, 131, 14, 19
121, 122, 71
3 Normal 16, 21, 4, 82, 
131, 52, 182, 
14, 10, 20, 15, 
9, 132, 11, 1, 
3, 62, 2
16, 4, 82, 52, 
182, 10, 20, 
15, 9, 132, 11, 
1,3, 62, 2
171, 172, 
16, 21, 4, 
82, 131, 52, 
182, 14, 10, 
20, 15, 9, 
132, 11, 1, 
181, 131, 19
4 Low 51, 61, 81 51, 61, 81 3, 62, 2, 51, 
61, 81
Table 23: Comparision of different cluster analysis routines
S.
No Level n Mean Cut off (AUCg)
1 High (IGR) 11 15369.545 >16000
2 Normal 15 13217 14000 - 16000
3 Low 3 10580 <12000
DISCUSSION
We carried out oral glucose tolerance test (OGTT-glucose / 
insulin) with 29 healthy female individuals for exploring parameters 
associated with impaired glucose regulation.  After over night fast, 
blood  samples  for  determinations  of  capillary  blood  glucose  and 
venous  blood  insulin  concentrations  are  taken  at  0,  30,60  and 
120mins  following  a  standard  oral  glucose  load  (75  g).  The 
observations  were  then  plotted  (Table:8).  The  differences  in  the 
shape of the OGTT curves were observed (Fig: 1). OGTT Curves of 
individuals  were  plotted  for  comparision  of  variability  in  blood 
glucose concentrations (Fig:2). 
Variations in glucose concentrations at time points 30 min, 60 
min (max) and 90 min were recorded (Fig:1,4&5). The fasting and 
2-hr  glucose  concentrations  for  all  the  subjects  did  not  differ 
significantly. The shape/pattern of the OGTT curves of subjects of 
NGR group were found to be similar without much variations in the 
blood glucose values within different time points (Fig:3).
We stratified the subjects into three groups by cluster analysis 
(Table:9 & Fig:6), polynomial (third order) fit (Fig:3 & 4) and area 
under curve (glucose) calculations (Table:10) to identify and study 
the subjects with altered glucose metabolism. 
OGTT  represents  whole  body  glucose  tolerance  &  insulin 
sensitivity while AUC glucose represents glucose that comes from 
HGP  &  unused  glucose.  The  subjects  were  clustered  into  three 
groups on the basis  of  all  the metabolic  variables by a computer 
program which permits direct visualization of the three dimensional 
shape of the data set and employed a cluster analysis technique.
Few subjects were found to have altered glucose metabolism 
(IGR  Group),  possibly  unrecognized  diabetes.  Almost  all  of  the 
subjects in the IGR group had a family history of diabetes. Based on 
current  WHO/ADA  criteria,  interpretation  all  cases  would  be 
considered  as  being  normal.  Since  neither  the  current  WHO  nor 
ADA criteria make allowance for what happens to blood sugar at 
one hour, the glucose profile of the subjects in the cluster 1 (IGR 
Group) would be considered as being entirely "normal" in spite of 
having abnormally shaped GTT curves.
The cutoff points of AUCg and 1-h PG concentrations for the 
three groups were then identified by reading from the figures and the 
corresponding  tables  (Table:8&10,  Fig:7&8).  The  values  are 
comparable  with  the  mean  AUCg  values  obtained  in  the  cluster 
analysis of NGR, IGR & all subjects groups (Table:10, 11,12 &13, 
Fig:8,12 &13).
The  correlation  between  AUCg and  1-h  PG concentrations 
were found to be high mainly  in the impaired  glucose regulation 
group making it  useful  for  differentiating it  from the NGR group 
(Fig:9,10&11). 
We tried to demonstrate the significance of the cutoff value at 
60min time point and the area under the curve of glucose (AUCg) 
during  OGTT  for  discrimination  of  various  degrees  of  glucose 
tolerance  (Fig:22,  23&24).  We  found  1-hr  GTT  glucose 
concentration contributed in above studies more than the values of 
other time points (Table: 10&11, Fig:8). Inclusion of ‘30 min OGTT 
insulin’  values  in  the  clustering  algorithm  improves  the  output 
marginally. So, we can conclude that the ‘60 min OGTT glucose’ 
values  alone  are  sufficient  to  stratify  the  data  and to  explore the 
altered glucose metabolism (Fig:18 and Table:18&19). We found a 
negative  linear  correlations  between  Insulin  30min  with  Glucose 
30min and Glucose 60min (Fig:19 &20).
Several  indices of ß-cell  responsivity and insulin sensitivity 
were  calculated  in  order  to  understand  the  altered  glucose 
metabolism  for  comparison  the  metabolic  profiles  of  groups 
(Table:20&21,  Fig  22).  We  attempted  to  explore  the  hyperbolic 
relationship between insulin release and ß-cell responsivity (Fig:21).
A  summary  table  is  presented  to  compare  different  cluster 
analysis  routines with various metabolic  variables  associated  with 
impaired glucose regulation (Table: 22 & 23).
SUMMARY AND CONCLUSION
The new term ‘pre-diabetes’  or impaired glucose regulation 
(IGR)  was  introduced  recently  and  refers  to  subjects  with  high 
fasting plasma glucose (FPG) concentration and normal response to 
a glucose load (IFG), subjects with abnormal postprandial glucose 
excursion but normal FPG concentration (IGT), and combination of 
IGT and IFG.
Research on insulin - glucose dynamics is gaining importance 
particularly in the area of diabetes prevention. Generally fasting & 2-
hour postprandial glucose concentrations are considered as reference 
points  for  the  diagnosis  of  diabetes  &  pre-diabetes.  American 
Diabetes  Associations  (ADA)  guidelines  rely  on  measurement  of 
fasting glucose (7.0 mmol/L) and the European & the WHO groups 
rely on glucose concentration at 2 hours of OGTT (11.1 mmol/L) in 
the screening and classification of glucose tolerance. However one-
hour glucose concentration is considered for screening and diagnosis 
of gestational diabetes in the US. Although fasting plasma glucose 
(FPG) alone does not always detect people with impaired glucose 
tolerance (IGT) and the 2-h plasma glucose (PG) does not always 
identify people with impaired fasting glucose (IFG), both tests are 
useful  in  terms  of  their  ability  to  detect  hyperglycemia  and  the 
consequences of disordered glucose metabolism.
Though  both  IFG  and  IGT  raise  risks  for  diabetes,  some 
controversies  still  exist  as  to  the  relative  contribution  of  insulin 
resistance  and  beta-cell  dysfunction  in  the  progression  from 
impaired glucose regulation (IGR) to diabetes. Insulin resistance and 
impaired  insulin  secretion  concur  toward  glucose  intolerance  and 
diabetes,  but  it  is  unclear  which defect  arises  first,  which relates 
more closely to IFG or IGT, and which reflects different alteration in 
glucose homeostasis.  Some reports showed that subjects with IFG 
had  hyperinsulinemia  and/or  worsening  of  insulin  resistance,  and 
those  with  IGT  had  defective  secretion  in  response  to  glucose 
loading,  while  other  reports  demonstrated  a  pronounced defect  in 
early insulin secretion in IFG and marked insulin resistance in IGT.
Insulin resistance  is  characterized by a  decreased ability  of 
insulin to stimulate the use of glucose by the muscle and adipose 
tissue,  where  the  suppression  of  lipase  controlled  by  insulin  is 
impaired. The consequent excessive supply of FFAs further affects 
glucose transportation in the skeletal muscles,  and inhibits insulin 
activity.  In  the  liver,  insulin  resistance  leads  to  increased  HGP, 
initially compensated by increased insulin secretion. If the process 
persists, glucotoxicity may occur, leading to chronic hyperglycemia 
and clinical diabetes.
 The OGTT has traditionally been used to classify the status of 
glucose tolerance for diagnostic purposes: normal glucose tolerance 
(NGT), IGT and diabetes based on the 2-h PG concentration. The 
ADA lowered the threshold for IFG from 6.1 mmol / L to 5.6 6.1 
mmol / L in order to detect more subjects with pre-diabetes. 
We carried out oral glucose tolerance test (OGTT-glucose / 
insulin) with 29 healthy female individuals for exploring parameters 
associated  with  impaired  glucose  regulation.   We  observed 
differences in the shape of their OGTT curves.  Variations in glucose 
concentrations at time points 30 min, 60 min (maximum) and 90 min 
were observed.  The fasting and 2-hr glucose concentrations for all 
the subjects  did not  differ  significantly.  We stratified the subjects 
into three groups by cluster analysis, polynomial (third order) fit and 
area  under  curve  (glucose)  calculations  to  identify  and  study  the 
subjects  with  altered  glucose  metabolism.  We  found  1-hr  GTT 
glucose  concentration  contributed  in  above studies  more  than the 
values of other time points.
Few subjects were found to have altered glucose metabolism 
(IGR  Group),  possibly  unrecognized  diabetes.  Almost  all  of  the 
subjects in the IGR group had a family history of diabetes. Based on 
current  WHO/ADA  criteria,  interpretation  all  cases  would  be 
considered  as  being  normal.  Since  neither  the  current  WHO  nor 
ADA criteria make allowance for what happens to blood sugar at 
one hour, the glucose profile of the subjects in the cluster 1 (IGR 
Group) would be considered as being entirely "normal" in spite of 
having  abnormally  shaped  GTT  curves.  We  calculated  several 
indices  of  ß-cell  responsivity  and  insulin  sensitivity   in  order  to 
understand  the  altered  glucose  metabolism  by  comparing  the 
metabolic  profiles  between  groups.  We  attempted  to  explore  the 
hyperbolic  relationship  between  insulin  release  and  ß-cell 
responsivity.
We tried to demonstrate the significance of the cutoff value at 
60min time point and the area under the curve of glucose (AUCg) 
during  OGTT  for  discrimination  of  various  degrees  of  glucose 
tolerance. The correlation between AUCg and 1-h PG concentrations 
were found to be high mainly  in the impaired  glucose regulation 
group  making  it  useful.  It  can  also  be  used  for  identifying 
individuals  with  subtypes  of  pre-diabetes  to  tailor  personalized 
treatments.  One hour OGTT glucose concentrations along with the 
values  of  insulin  sensitivity  indices  may  help  us  to  understand 
gestational  diabetes  mellitus,  PCOS  and  patients  of  undiagnosed 
diabetes mellitus with AMI (acute myocardial infarction). Recently, 
1-h  hyperglycemia  (1hPG)  during  an  oral  glucose  tolerance  test 
(OGTT) with a cut point of 155 mg/dl has been indicated as a further 
risk  factor  for  type2  diabetes  and  showed  early  carotid 
atherosclerosis. The Honolulu series of studies, showed the one-hour 
plasma glucose concentration to be an independent risk factor  for 
ischemic heart disease, stroke, and sudden death. They also reported 
that the vascular risk attached to the one-hour glucose concentration 
closely  followed  a  gradient  pattern  with,  a  direct  dose-response 
relationship.
A clearer understanding of the pathophysiologic abnormalities which 
characterize IGT and IFG provides insights about interventions to 
slow/halt the progression to type2 diabetes. 
• Subjects  with  IFG,  who manifest  predominant  liver  insulin 
resistance,  are  most  likely  to  benefit  from  agents,  e.g., 
metformin, that reduce hepatic insulin resistance. 
• Subjects  with IGT,  who predominantly  have muscle  insulin 
resistance plus severely impaired insulin secretion, are more 
likely  to  respond  to  agents  that  improve  skeletal  muscle 
insulin  resistance,  such  as  PPAR-  gamma  agonists,  in 
combination  with  an  insulin  secretagogue,  such  as  GLP-1 
analog. 
• Both IFG and IGT are characterized by a reduction in early-
phase  insulin  secretion,  while  subjects  with  IGT also  have 
impaired late-phase insulin secretion. 
We  conclude  that  although  the  number  of  subjects  studied 
might be considered relatively small  and the data preliminary, the 
elevated plasma glucose at one hour in the presence of an otherwise 
non-diabetic OGTT profile can be used as a diagnostic point in the 
detection and classification of glucose intolerance & as a predictor 
of long term macrovascular complications. Further study on subjects 
with  elevated  one-hour  glucose  concentration  is  to  be  done  to 
determine the natural history of the abnormality in relation to the 
development  of  diabetic  complications.  The  acute  postprandial 
hyperglycemia at one hour might in itself be a risk factor. 
Timely effective interventions / measures and screening tests 
for  complications at  the time of diagnosis  become imperative not 
only for early detection, but also to prevent progression to end stage 
disease. Life style changes/interventions utilizing low glycemic, high 
fibre  carbohydrates  may  be  useful  in  preventing  and  treating  all 
diseases of insulin resistance. Metformin has been shown to lower 
the risk of  myocardial  infarction and all-cause  mortality  by more 
than 30% in patients  with type2 diabetes  and obesity,  as  well  as 
having  a  beneficial  effect  on  the  lipid  profile.  Drugs  such  as  ß 
blockers and high dose thiazides exacerbate insulin resistance unlike 
ACE inhibitors and β- blockers.
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